<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Endocrinol (Lausanne)</journal-id><journal-id journal-id-type="iso-abbrev">Front Endocrinol (Lausanne)</journal-id><journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id><journal-title-group><journal-title>Frontiers in Endocrinology</journal-title></journal-title-group><issn pub-type="epub">1664-2392</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4528200</article-id><article-id pub-id-type="doi">10.3389/fendo.2015.00115</article-id><article-categories><subj-group subj-group-type="heading"><subject>Endocrinology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Insights into Orphan Nuclear Receptors as Prognostic Markers and Novel Therapeutic Targets for Breast Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Aesoy</surname><given-names>Reidun</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/247261"/></contrib><contrib contrib-type="author"><name><surname>Clyne</surname><given-names>Colin D.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/119758"/></contrib><contrib contrib-type="author"><name><surname>Chand</surname><given-names>Ashwini L.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/133579"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Cancer Drug Discovery, Hudson Institute of Medical Research</institution>, <addr-line>Melbourne, VIC</addr-line>, <country>Australia</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Biomedicine, University of Bergen</institution>, <addr-line>Bergen</addr-line>, <country>Norway</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Molecular and Translational Science, Monash University</institution>, <addr-line>Clayton, VIC</addr-line>, <country>Australia</country></aff><aff id="aff4"><sup>4</sup><institution>Cancer and Inflammation Laboratory, Olivia Newton-John Cancer Research Institute</institution>, <addr-line>Melbourne, VIC</addr-line>, <country>Australia</country></aff><aff id="aff5"><sup>5</sup><institution>School of Cancer Medicine, La Trobe University</institution>, <addr-line>Melbourne, VIC</addr-line>, <country>Australia</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Gabriella Castoria, Second University of Naples, Italy</p></fn><fn fn-type="edited-by"><p>Reviewed by: Wen Zhou, Columbia University, USA; Pia Giovannelli, Second University of Naples, Italy</p></fn><corresp content-type="corresp" id="cor1">*Correspondence: Ashwini L. Chand, <email>ashwini.chand@onjcri.org.au</email></corresp><fn fn-type="other" id="fn001"><p>Specialty section: This article was submitted to Cancer Endocrinology, a section of the journal Frontiers in Endocrinology</p></fn></author-notes><pub-date pub-type="epub"><day>07</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>6</volume><elocation-id>115</elocation-id><history><date date-type="received"><day>04</day><month>6</month><year>2015</year></date><date date-type="accepted"><day>11</day><month>7</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 Aesoy, Clyne and Chand.</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Aesoy, Clyne and Chand</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>There is emerging evidence asserting the importance of orphan nuclear receptors (ONRs) in cancer initiation and progression. In breast cancer, there is a lot unknown about ONRs in terms of their expression profile and their transcriptional targets in the various stages of tumor progression. With the classification of breast tumors into distinct molecular subtypes, we assess ONR expression in the different breast cancer subtypes and with patient outcomes. Complementing this, we review evidence implicating ONR-dependent molecular pathways in breast cancer progression to identify candidate ONRs as potential prognostic markers and/or as therapeutic targets.</p></abstract><kwd-group><kwd>orphan nuclear receptors</kwd><kwd>breast cancer</kwd><kwd>transcription factors</kwd><kwd>breast cancer subtypes</kwd><kwd>small molecule inhibitors</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Victorian Government&#x02019;s Opera-tional Infrastructure Support Program</funding-source></award-group><award-group><funding-source id="cn002">National Health and Medical Research Council of Australia</funding-source></award-group><award-group><funding-source id="cn003">NHMRC</funding-source><award-id rid="cn003">ID 1062247</award-id></award-group></funding-group><counts><fig-count count="0"/><table-count count="3"/><equation-count count="0"/><ref-count count="130"/><page-count count="11"/><word-count count="9906"/></counts></article-meta></front><body><sec sec-type="intro" id="S1"><title>Introduction</title><p>Breast cancer is the most common cancer in women worldwide. Nearly 1.7 million new cases diagnosed in 2012 accounted for 12% of all new cancer cases and 25% of all cancers in women (<xref rid="B1" ref-type="bibr">1</xref>). The incidence of breast cancer is expected to increase primarily due to changes to the demographic with increasing aging populations and obesity, key risk factors for breast cancer. While patients with primary breast cancer are treated successfully, it is in the treatment of recurrent and invasive tumors where there is a clear need for the development of new therapies. Here, we discuss the potential of members of the nuclear receptor (NR) family as druggable targets for the discovery of new treatments in breast cancer.</p><p>The growth of the primary tumor in the breast is predominantly dependent on estrogen (<xref rid="B2" ref-type="bibr">2</xref>), via its interaction with its target receptor, the estrogen receptor (ER), expressed in 75% of all breast cancers. Hence, endocrine therapy is currently the most effective adjuvant treatment for ER-positive breast cancer. These include selective ER modulators (SERMs), selective ER down-regulators (SERDs), and aromatase inhibitors (AIs) all of which target the estrogen action and biosynthesis pathways (<xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>). Despite the success of endocrine treatments in breast cancer, patients often present with resistance to endocrine therapy, despite high tumor ER expression. Furthermore, approximately 70% of patients with advanced disease ultimately acquire resistance to endocrine therapy [reviewed by Musgrove and Sutherland (<xref rid="B6" ref-type="bibr">6</xref>)]. The mechanisms for <italic>de novo</italic> or acquired endocrine therapy resistance are still poorly understood and may involve mechanisms of crosstalk between ER and other cell signaling networks, e.g., the Human Epidermal Growth Factor Receptor (HER) pathways. The actions of ER, Progesterone Receptor (PR), and Androgen Receptor (AR) in mediating breast cancer growth are well described in the literature. However, often overlooked in this context are the other members of the NR superfamily that function as transcription factors in regulating steroidogenesis, proliferation, and invasion and migration properties of cancer cells. The focus of the current review is to interrogate the expression patterns of the orphan nuclear receptors (ONR) and &#x0201c;adopted ONRs&#x0201d; in breast cancer, identify correlations with patient outcomes, and review the literature for functional evidence that may identify new ONRs as potentially linked to breast cancer in a prognostic sense or potential therapeutic targets.</p><p>Orphan NRs, referred to as ONRs throughout this review (Table <xref ref-type="table" rid="T1">1</xref>), form a subgroup within the NR superfamily (<xref rid="B7" ref-type="bibr">7</xref>). Unlike the NRs, that are ligand activated; the ONRs have been classified together due to the lack of known endogenous ligands or other interacting synthetic compounds and drugs. Table <xref ref-type="table" rid="T1">1</xref> provides an overview of the ONR and adopted ONRs along with the potential endogenous or synthetic ligands that have been identified. While functioning in a similar manner to NRs, the ONRs can dimerize and bind to NR response elements (consisting of two palindromic NR half sites) to mediate transcription. As with NRs, ONRs can also hetero-dimerize, however it is ONRs that bind to NR half sites as monomers. Within the ONRs, the term &#x0201c;adopted ONRs&#x0201d; describes ONRs for which endogenous ligand or synthetic compounds have now been identified and shown to modulate activity (<xref rid="B7" ref-type="bibr">7</xref>&#x02013;<xref rid="B9" ref-type="bibr">9</xref>) (Table <xref ref-type="table" rid="T1">1</xref>). Structural analysis of ONRs also demonstrates that certain NRs, such as NR5A1 and NR5A2 are held in a constitutively active confirmation to maintain ligand-independent activity (<xref rid="B10" ref-type="bibr">10</xref>&#x02013;<xref rid="B14" ref-type="bibr">14</xref>). Furthermore, modulation of the activity of NRs and ONRs by co-regulator proteins such as Nuclear Receptor Co-activators (NCOAs 1&#x02013;3, also termed steroid receptor co-activators or SRCs 1&#x02013;3), form an essential component of functional modulation to dictate whether genes are actively transcribed or repressed (<xref rid="B15" ref-type="bibr">15</xref>&#x02013;<xref rid="B17" ref-type="bibr">17</xref>). The identification of synthetic compounds to modulate ONR activity is testament to the druggability of this class of transcription factors making them an attractive target for drug development in cancer. Due to their druggability and wide-ranging cellular functions, there is considerable interest in identifying novel ligands for ONRs as a therapeutic tool.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><bold>Orphan nuclear receptors and proposed ligands</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Gene symbol</th><th valign="top" align="left" rowspan="1" colspan="1">Common name</th><th valign="top" align="left" rowspan="1" colspan="1">Potential ligand(s)</th><th valign="top" align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">NR0B1</td><td align="left" valign="top" rowspan="1" colspan="1">DAX-1</td><td align="left" valign="top" rowspan="1" colspan="1">Not known</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR0B2</td><td align="left" valign="top" rowspan="1" colspan="1">SHP</td><td align="left" valign="top" rowspan="1" colspan="1">CD437 Retinoids<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="B17" ref-type="bibr">17</xref>&#x02013;<xref rid="B20" ref-type="bibr">20</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR1D1</td><td align="left" valign="top" rowspan="1" colspan="1">Rev-Erb&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">Heme<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="B21" ref-type="bibr">21</xref>&#x02013;<xref rid="B25" ref-type="bibr">25</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR1D2</td><td align="left" valign="top" rowspan="1" colspan="1">Rev-Erb&#x003b2;</td><td align="left" valign="top" rowspan="1" colspan="1">Heme<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="B21" ref-type="bibr">21</xref>&#x02013;<xref rid="B25" ref-type="bibr">25</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR1F1</td><td align="left" valign="top" rowspan="1" colspan="1">ROR&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">Isoflavones, Cholesterol, derivatives</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="B26" ref-type="bibr">26</xref>&#x02013;<xref rid="B28" ref-type="bibr">28</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR1F2</td><td align="left" valign="top" rowspan="1" colspan="1">ROR&#x003b2;</td><td align="left" valign="top" rowspan="1" colspan="1">all-trans retinoic acid (ATRA)</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="B29" ref-type="bibr">29</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR1F3</td><td align="left" valign="top" rowspan="1" colspan="1">ROR&#x003b3;</td><td align="left" valign="top" rowspan="1" colspan="1">Isoflavones</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="B28" ref-type="bibr">28</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2A1</td><td align="left" valign="top" rowspan="1" colspan="1">HNF4&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">Fatty acids</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2A2</td><td align="left" valign="top" rowspan="1" colspan="1">HNF4&#x003b3;</td><td align="left" valign="top" rowspan="1" colspan="1">Fatty acids</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="B31" ref-type="bibr">31</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2C1</td><td align="left" valign="top" rowspan="1" colspan="1">TR2</td><td align="left" valign="top" rowspan="1" colspan="1">Not known</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2C2</td><td align="left" valign="top" rowspan="1" colspan="1">TR4</td><td align="left" valign="top" rowspan="1" colspan="1">Retinol/ATRA<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="B32" ref-type="bibr">32</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2E1</td><td align="left" valign="top" rowspan="1" colspan="1">TLX</td><td align="left" valign="top" rowspan="1" colspan="1">Ccrps: small molecule agonists</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="B33" ref-type="bibr">33</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2E3</td><td align="left" valign="top" rowspan="1" colspan="1">PNR</td><td align="left" valign="top" rowspan="1" colspan="1">Benzimidazoles</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2F1</td><td align="left" valign="top" rowspan="1" colspan="1">COUP-TF-I</td><td align="left" valign="top" rowspan="1" colspan="1">Not known</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2F2</td><td align="left" valign="top" rowspan="1" colspan="1">COUP-TF-II</td><td align="left" valign="top" rowspan="1" colspan="1">Retinol/ATRA<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="B36" ref-type="bibr">36</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2F6</td><td align="left" valign="top" rowspan="1" colspan="1">EAR2</td><td align="left" valign="top" rowspan="1" colspan="1">Not known</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR3B1</td><td align="left" valign="top" rowspan="1" colspan="1">ERR&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">Isoflavones, Diethylstilbestrol (DES), Chlordane</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="B37" ref-type="bibr">37</xref>&#x02013;<xref rid="B39" ref-type="bibr">39</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR3B2</td><td align="left" valign="top" rowspan="1" colspan="1">ERR&#x003b2;</td><td align="left" valign="top" rowspan="1" colspan="1">Isoflavones, DES, 4-Hydroxy tamoxifen (4HT)</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR3B3</td><td align="left" valign="top" rowspan="1" colspan="1">ERR gamma</td><td align="left" valign="top" rowspan="1" colspan="1">Isoflavones, DES, 4HT</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B40" ref-type="bibr">40</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR4A1</td><td align="left" valign="top" rowspan="1" colspan="1">NGFI-B</td><td align="left" valign="top" rowspan="1" colspan="1">Cytosporone B<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>, Diindolylmethane Analogs (C-DMIs)</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="B41" ref-type="bibr">41</xref>&#x02013;<xref rid="B47" ref-type="bibr">47</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR4A2</td><td align="left" valign="top" rowspan="1" colspan="1">NURR1</td><td align="left" valign="top" rowspan="1" colspan="1">Benzimidazoles, C-DMIs, 6-Mercaptopurine</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="B48" ref-type="bibr">48</xref>&#x02013;<xref rid="B51" ref-type="bibr">51</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR4A3</td><td align="left" valign="top" rowspan="1" colspan="1">NOR1</td><td align="left" valign="top" rowspan="1" colspan="1">6-Mercaptopurine, Prostaglandin A2</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B53" ref-type="bibr">53</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR5A1</td><td align="left" valign="top" rowspan="1" colspan="1">SF-1</td><td align="left" valign="top" rowspan="1" colspan="1">Phospholipids</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR5A2</td><td align="left" valign="top" rowspan="1" colspan="1">LRH-1</td><td align="left" valign="top" rowspan="1" colspan="1">Phospholipids</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B54" ref-type="bibr">54</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR6A1</td><td align="left" valign="top" rowspan="1" colspan="1">GCNF</td><td align="left" valign="top" rowspan="1" colspan="1">Not known</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn1"><p><italic><sup>a</sup>Compounds or proteins that bind the ONR</italic>.</p></fn><p><italic>Potential ligands are defined as those proposed to bind and modulate ONR transcriptional activity</italic>.</p></table-wrap-foot></table-wrap><p>Given the roles of ONRs in regulating transcription of genes involved in processes important for development, metabolism, immunity, angiogenesis, steroidogenesis, and fertility, their actions have also been implicated in multiple diseases including diverse types of cancers. Although not widely reported, there is emerging but clear evidence of ONR-dependent mechanisms in the regulation of tumor growth and progression. Recent work quantifying the expression profiles of the NR superfamily members in well curated tumor biopsy tissue and isolated cancer-associated fibroblast (CAFs) now allow a good insight into the possible actions of NRs in the development and progression of breast cancer (<xref rid="B55" ref-type="bibr">55</xref>&#x02013;<xref rid="B57" ref-type="bibr">57</xref>).</p><p>We analyzed datasets available online to establish correlations between ONR expression and clinical parameters that define breast cancer outcomes. We also present an overview of the current understanding of ONR-related cellular mechanisms in breast cancer development.</p></sec><sec id="S2"><title>Molecular Signatures Defining Breast Cancers</title><p>There are now several intrinsic molecular signatures acquired by genome-wide expression profiling of breast tumors that are used to stratify the heterogeneity of breast cancers (<xref rid="B58" ref-type="bibr">58</xref>&#x02013;<xref rid="B62" ref-type="bibr">62</xref>). A clear delineation of these multi-gene signatures will ultimately allow personalized therapies. Breast tumors are classified into a variety of molecular subtypes with the four major subtypes being Luminal A, Luminal B, HER2-enriched, and basal-like tumors. Luminal A and Luminal B subtypes are both ER-positive tumors;&#x02009;Luminal A tumors being less aggressive than the Luminal B subtype, and more responsive to endocrine therapies (<xref rid="B63" ref-type="bibr">63</xref>&#x02013;<xref rid="B66" ref-type="bibr">66</xref>). HER2-enriched tumors show amplification of the <italic>HER2</italic> gene and these patients respond well to treatment that target HER2. High ER and PR levels, the lack of <italic>HER2</italic> amplification in low-grade tumors and specific gene signatures, are now used as indicators of good effectiveness with endocrine therapy (<xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B62" ref-type="bibr">62</xref>). Basal-like tumors, also known as Triple-Negative Breast Cancers (TNBCs, lacking expression of ER, PR and HER2) are aggressive tumors with the only treatment options being surgery and chemotherapy.</p><p>In this vein, to address the question that other NRs could be used to further classify tumor subtypes, recently, three key studies provide a comprehensive expression profile of the NR superfamily and their interacting co-regulatory proteins in tumor and associated stroma in breast cancer (<xref rid="B55" ref-type="bibr">55</xref>&#x02013;<xref rid="B57" ref-type="bibr">57</xref>). Based on these publications, akin to ER status, the expression of other NRs and ONRs could very likely provide additional prognostic power in the classification of breast tumor subtypes.</p></sec><sec id="S3"><title>Correlation of ONR mRNA Transcript Expression with Patient Survival Outcomes</title><p>We used publically available Kaplan&#x02013;Meier Plotter<xref ref-type="fn" rid="fn1"><sup>1</sup></xref> and BreastMark<xref ref-type="fn" rid="fn2"><sup>2</sup></xref> algorithms to correlate ONR gene expression to clinical outcomes within the datasets available within the two platforms as indicated in Tables <xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>. Kaplan&#x02013;Meier Plot analysis was used specifically to assess ONR expression in relation to relapse free survival (RFS) in breast cancer patients; analysis also stratified to ER-positive and ER-negative status from gene expression data and survival information of 1,809 patients collated from GEO (Affymetrix HGU133A and HGU133 Plus 2.0 microarrays) EGA and TCGA databases (<xref rid="B67" ref-type="bibr">67</xref>). With the BreastMark algorithm, mRNA expression patterns of the genes of interest can be classified within breast cancer subtypes according to the PAM50 molecular signature (<xref rid="B68" ref-type="bibr">68</xref>). The database integrates gene expression and survival data from 26 datasets from 12 microarray platforms corresponding to 4,738 samples. We utilized the database to identify ONRs in which mRNA expression levels were positively or negatively correlated with disease progression in all breast cancer or stratified into the various subtypes.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p><bold>Correlation of ONR expression to DFS in breast cancer patients</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Gene symbol</th><th valign="top" align="left" rowspan="1" colspan="1">Common name</th><th valign="top" align="left" rowspan="1" colspan="1">As a whole</th><th valign="top" align="left" rowspan="1" colspan="1">Node pos</th><th valign="top" align="left" rowspan="1" colspan="1">Node neg</th><th valign="top" align="left" rowspan="1" colspan="1">LumA</th><th valign="top" align="left" rowspan="1" colspan="1">LumB</th><th valign="top" align="left" rowspan="1" colspan="1">Her2 pos</th><th valign="top" align="left" rowspan="1" colspan="1">Basal</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">NR0B1</td><td align="left" valign="top" rowspan="1" colspan="1">DAX-1</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR0B2</td><td align="left" valign="top" rowspan="1" colspan="1">SHP</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.022<xref ref-type="table-fn" rid="tfn2"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.004<xref ref-type="table-fn" rid="tfn2"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR1D1</td><td align="left" valign="top" rowspan="1" colspan="1">REV-ERB alpha</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.015<xref ref-type="table-fn" rid="tfn3">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR1D2</td><td align="left" valign="top" rowspan="1" colspan="1">REV-ERB beta</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.030<xref ref-type="table-fn" rid="tfn2"><sup>#</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR1F1</td><td align="left" valign="top" rowspan="1" colspan="1">ROR alpha</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR1F2</td><td align="left" valign="top" rowspan="1" colspan="1">ROR beta</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.011<xref ref-type="table-fn" rid="tfn2"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR1F3</td><td align="left" valign="top" rowspan="1" colspan="1">ROR gamma</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2A1</td><td align="left" valign="top" rowspan="1" colspan="1">HNF4 alpha</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.035<xref ref-type="table-fn" rid="tfn3">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2A2</td><td align="left" valign="top" rowspan="1" colspan="1">HNF4 gamma</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.001<xref ref-type="table-fn" rid="tfn3">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.023<xref ref-type="table-fn" rid="tfn3">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2C1</td><td align="left" valign="top" rowspan="1" colspan="1">TR2</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.035<xref ref-type="table-fn" rid="tfn3">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2C2</td><td align="left" valign="top" rowspan="1" colspan="1">TR4</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2E1</td><td align="left" valign="top" rowspan="1" colspan="1">TLX</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.003<xref ref-type="table-fn" rid="tfn2"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2E3<xref ref-type="table-fn" rid="tfn4">**</xref></td><td align="left" valign="top" rowspan="1" colspan="1">PNR</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2F1</td><td align="left" valign="top" rowspan="1" colspan="1">COUP-TF-I</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2F2</td><td align="left" valign="top" rowspan="1" colspan="1">COUP-TF-II</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.009<xref ref-type="table-fn" rid="tfn2"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2F6</td><td align="left" valign="top" rowspan="1" colspan="1">EAR2</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.038<xref ref-type="table-fn" rid="tfn2"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR3B1</td><td align="left" valign="top" rowspan="1" colspan="1">ERR alpha</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.009<xref ref-type="table-fn" rid="tfn3">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.019<xref ref-type="table-fn" rid="tfn3">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR3B2</td><td align="left" valign="top" rowspan="1" colspan="1">ERR beta</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.01<xref ref-type="table-fn" rid="tfn2"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR3B3</td><td align="left" valign="top" rowspan="1" colspan="1">ERR gamma</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.01<xref ref-type="table-fn" rid="tfn2"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR4A1</td><td align="left" valign="top" rowspan="1" colspan="1">NUR77</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR4A2</td><td align="left" valign="top" rowspan="1" colspan="1">NURR1</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.003<xref ref-type="table-fn" rid="tfn2"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.007<xref ref-type="table-fn" rid="tfn2"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR4A3</td><td align="left" valign="top" rowspan="1" colspan="1">NOR1</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.003<xref ref-type="table-fn" rid="tfn2"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR5A1</td><td align="left" valign="top" rowspan="1" colspan="1">SF-1</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.025<xref ref-type="table-fn" rid="tfn2"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR5A2</td><td align="left" valign="top" rowspan="1" colspan="1">LRH-1</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.003<xref ref-type="table-fn" rid="tfn3">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR6A1</td><td align="left" valign="top" rowspan="1" colspan="1">GCNF</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.015<xref ref-type="table-fn" rid="tfn2"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td></tr></tbody></table><table-wrap-foot><p><italic>Based on BreastMark mRNA analysis (<uri xlink:type="simple" xlink:href="http://glados.ucd.ie/BreastMark/mRNA_analysis.html">http://glados.ucd.ie/BreastMark/mRNA_analysis.html</uri>)</italic>.</p><p><italic>Significance; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, ns&#x02009;=&#x02009;non-significant; <italic>p</italic>&#x02009;&#x02265;&#x02009;0.05</italic>.</p><fn id="tfn2"><p><italic><sup>#</sup>Higher ONR expression is significantly correlated with increased survival in BCa patients</italic>.</p></fn><fn id="tfn3"><p><italic>*Lower ONR expression is significantly correlated with increased survival in BCa patients</italic>.</p></fn><fn id="tfn4"><p><italic>**Not included in the database. DFS, disease free survival; BCa, breast cancer</italic>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p><bold>Correlation of ONR expression to RFS in breast cancer patients</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Gene symbol</th><th valign="top" align="left" rowspan="1" colspan="1">Common name</th><th valign="top" align="left" rowspan="1" colspan="1">All BCa</th><th valign="top" align="left" rowspan="1" colspan="1">ER-positive BCa</th><th valign="top" align="left" rowspan="1" colspan="1">ER-negative BCa</th><th valign="top" align="left" rowspan="1" colspan="1">Affy ID</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">NR0B1</td><td align="left" valign="top" rowspan="1" colspan="1">DAX-1</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.0001<xref ref-type="table-fn" rid="tfn5"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">206645_s_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR0B2</td><td align="left" valign="top" rowspan="1" colspan="1">SHP</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;3.5e<sup>&#x02212;7#</sup></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">206410_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR1D1</td><td align="left" valign="top" rowspan="1" colspan="1">REV-ERB alpha</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;9.1e<sup>&#x02212;5#</sup></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">31637_s_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR1D2</td><td align="left" valign="top" rowspan="1" colspan="1">REV-ERB beta</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;1e<sup>&#x02212;4</sup>*</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">209750_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR1F1</td><td align="left" valign="top" rowspan="1" colspan="1">ROR alpha</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.004<xref ref-type="table-fn" rid="tfn5"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">210426_x_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR1F2</td><td align="left" valign="top" rowspan="1" colspan="1">ROR beta</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.0002<xref ref-type="table-fn" rid="tfn5"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">206443_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR1F3</td><td align="left" valign="top" rowspan="1" colspan="1">ROR gamma</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0<xref ref-type="table-fn" rid="tfn5"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.002<xref ref-type="table-fn" rid="tfn5"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">206419_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2A1</td><td align="left" valign="top" rowspan="1" colspan="1">HNF4 alpha</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;2.9<sup>&#x02212;5#</sup></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">208429_x_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2A2</td><td align="left" valign="top" rowspan="1" colspan="1">HNF4 gamma</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;1.8e<sup>&#x02212;6#</sup></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">207456_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2C1</td><td align="left" valign="top" rowspan="1" colspan="1">TR2</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">204791_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2C2</td><td align="left" valign="top" rowspan="1" colspan="1">TR4</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.0036<xref ref-type="table-fn" rid="tfn5"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">206038_s_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2E1</td><td align="left" valign="top" rowspan="1" colspan="1">TLX</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.0062<xref ref-type="table-fn" rid="tfn5"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.0008<xref ref-type="table-fn" rid="tfn5"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">207443_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2E3</td><td align="left" valign="top" rowspan="1" colspan="1">PNR</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.0036<xref ref-type="table-fn" rid="tfn5"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">208385_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2F1</td><td align="left" valign="top" rowspan="1" colspan="1">COUP-TF-I</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.0029<xref ref-type="table-fn" rid="tfn5"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">209506_s_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2F2</td><td align="left" valign="top" rowspan="1" colspan="1">COUP-TF-II</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.034<xref ref-type="table-fn" rid="tfn6">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">209120_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR2F6</td><td align="left" valign="top" rowspan="1" colspan="1">EAR2</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">209262_s_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR3B1</td><td align="left" valign="top" rowspan="1" colspan="1">ERR alpha</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">1487_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR3B2</td><td align="left" valign="top" rowspan="1" colspan="1">ERR beta</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;2.2e<sup>&#x02212;7#</sup></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">207726_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR3B3<xref ref-type="table-fn" rid="tfn7">**</xref></td><td align="left" valign="top" rowspan="1" colspan="1">ERR gamma</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Not available</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR4A1</td><td align="left" valign="top" rowspan="1" colspan="1">NUR77</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;1.5e<sup>&#x02212;5#</sup></td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.013<xref ref-type="table-fn" rid="tfn5"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">202340_x_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR4A2</td><td align="left" valign="top" rowspan="1" colspan="1">NURR1</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;1.7e<sup>&#x02212;8#</sup></td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.0054<xref ref-type="table-fn" rid="tfn5"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">216248_s_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR4A3</td><td align="left" valign="top" rowspan="1" colspan="1">NOR1</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic>&#x02009;=&#x02009;0.0067<xref ref-type="table-fn" rid="tfn5"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.014<xref ref-type="table-fn" rid="tfn5"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">209959_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR5A1</td><td align="left" valign="top" rowspan="1" colspan="1">SF-1</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.046<xref ref-type="table-fn" rid="tfn5"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">210333_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR5A2</td><td align="left" valign="top" rowspan="1" colspan="1">LRH-1</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;5.8e<sup>&#x02212;12#</sup></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">208337_s_at</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NR6A1</td><td align="left" valign="top" rowspan="1" colspan="1">GCNF</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.0003<xref ref-type="table-fn" rid="tfn5"><sup>#</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">ns</td><td align="left" valign="top" rowspan="1" colspan="1">207742_s_at</td></tr></tbody></table><table-wrap-foot><p><italic>Table is based on KM Plot per April 2015 (<uri xlink:type="simple" xlink:href="http://kmplot.com/analysis/index.php?p=service&#x00026;cancer=breast">http://kmplot.com/analysis/index.php?p=service&#x00026;cancer=breast</uri>)</italic>.</p><p>Significance; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, ns&#x02009;=&#x02009;non-significant; <italic>p</italic>&#x02009;&#x02265;&#x02009;0.05</p><fn id="tfn5"><p><italic><sup>#</sup>Higher ONR expression is significantly correlated with increased survival in BCa patients</italic>.</p></fn><fn id="tfn6"><p><italic>*Lower ONR expression is significantly correlated with increased survival in BCa patients</italic>.</p></fn><fn id="tfn7"><p><italic>**Not included in the database. RFS, relapse free survival; BCa, breast cancer</italic>.</p></fn></table-wrap-foot></table-wrap><sec id="S3-1"><title>ONRs associated with the luminal A subtype</title><p>Lower expression of Hepatocyte Nuclear Factor 4 alpha (HNF&#x003b1;, NR2A1) and higher expression of V-erbA related protein (EAR2, NR2F6) were associated with increased DFS in patients with the Luminal A subtype of breast cancer (<italic>p</italic>&#x02009;=&#x02009;0.035 and <italic>p</italic>&#x02009;=&#x02009;0.038, respectively, Table <xref ref-type="table" rid="T2">2</xref>). The functions of these two ONRs in the context of breast cancer are not defined as yet, although HNF4&#x003b1;, a key transcriptional regulator of hepatocyte differentiation and function in liver, acts as a tumor suppressor in the diethylinitrosamine-induced rat model of liver carcinogenesis, and inhibits epithelial-mesenchymal transition (EMT) (<xref rid="B69" ref-type="bibr">69</xref>). In a recent study focusing on expression patterns of genes associated with altered metabolism of breast cancer cells (using the TCGA database), the analysis of 556 transcription factor sequence motifs identified HNF4&#x003b1;-specific response elements as enriched in differentially co-expressed gene targets (<xref rid="B70" ref-type="bibr">70</xref>). Interestingly, this data suggest a potential function for this ONR in breast cancer cells in mediating tumor proliferation via the regulation of cellular metabolism, and warrants further investigation.</p><p>EAR2 is a member of the COUP-TF orphan subfamily and its established functions include negative regulation of renin and the luteinizing hormone receptor gene transcription and brain function including memory and learning (<xref rid="B71" ref-type="bibr">71</xref>&#x02013;<xref rid="B74" ref-type="bibr">74</xref>). EAR2 expression is highly expressed in both ER-positive and ER-negative tumors relative to normal breast tissue (<xref rid="B57" ref-type="bibr">57</xref>). Additionally, EAR2 has been shown to directly interact with the aromatase promoter and down-regulate the expression of aromatase in breast cancer cell lines (<xref rid="B75" ref-type="bibr">75</xref>).</p></sec><sec id="S3-2"><title>ONRs associated with the luminal B subtype</title><p>Within the BreastMark criteria, reduced expression of REV-ERB&#x003b1;, TR2, LRH-1, and increased ROR&#x003b2; and SHP expression are significantly associated with greater DFS in patients in Luminal B tumors (<italic>p</italic>&#x02009;=&#x02009;0.015, <italic>p</italic>&#x02009;=&#x02009;0.035, <italic>p</italic>&#x02009;=&#x02009;0.003, <italic>p</italic>&#x02009;=&#x02009;0.011, <italic>p</italic>&#x02009;=&#x02009;0.004, <italic>p</italic>&#x02009;=&#x02009;0.025 and <italic>p</italic>&#x02009;=&#x02009;0.003, respectively, Table <xref ref-type="table" rid="T2">2</xref>). In contrast to Luminal A tumors, a greater number ONRs are associated with the Luminal B subtype, a more aggressive tumor and patients are often resistant to treatment. The functional implications of these expression profiles for each ONR associations are discussed in detail below.</p><p>REV-ERB&#x003b1; (also known as NR1D1) is a transcriptional repressor, abundantly expressed in adipose tissue and its functions are linked mainly to adipocyte differentiation, regulation of cell metabolism, and thermogenic responses (<xref rid="B76" ref-type="bibr">76</xref>) REV-ERB&#x003b1; lacks a transcriptional activation domain and represses target genes via its interaction with the transcriptional corepressor N-CoR. REV-ERB&#x003b1; has been shown to have a prosurvival function in HER2-positive breast cancer cells (<xref rid="B77" ref-type="bibr">77</xref>). However, recently it has been shown that REV-ERB&#x003b2; (NR1D2) is also expressed in breast cancer cell lines and that its expression not correlated with HER2 or ER expression (<xref rid="B9" ref-type="bibr">9</xref>). Furthermore, the identification of a novel REV-ERB&#x003b2; inhibitor, ARN5187, results in tumor cell cytotoxicity suggesting anticancer effects of REV-ERB&#x003b2; suppression (<xref rid="B9" ref-type="bibr">9</xref>). We observed higher expression of REV-ERB&#x003b2; as significantly associated with increased DFS in the basal cancer subtype (<italic>p</italic>&#x02009;=&#x02009;0.03). Further determination of the protein expression and function of the two REV-ERB isoforms would allow a better understanding of the roles these ONRs play in the different breast cancer subtypes particularly with regards to HER2 status. Given its significant interaction with multiple co-regulators in ER-negative breast tumors, and a significant correlation to predict poorer outcome for patients, further investigation of the two REV-ERB isoforms in breast cancer is warranted.</p><p>Similarly to REV-ERB isoforms, TR2 (NR2C1) is a transcriptional repressor, and inhibits ER&#x003b1;-mediated transcription to regulate cell proliferation in breast cancer cells (<xref rid="B78" ref-type="bibr">78</xref>). In transgenic mouse models where TR2 is either over-expressed or down regulated, TR2 was identified as a key transcriptional repressor of GATA1 (<xref rid="B79" ref-type="bibr">79</xref>). Therefore, reduced TR2 in tumors may be the mechanism via which increased GATA1 promotes a more aggressive tumor phenotype in breast cancers (<xref rid="B80" ref-type="bibr">80</xref>). However, it is the lower expression of TR2 that was associated with increased survival in women with Luminal B tumors (Table <xref ref-type="table" rid="T2">2</xref>, <italic>p</italic>&#x02009;=&#x02009;0.035). Further investigation of the protein localization and correlation to TR2 mRNA expression profiles and the identification of breast cancer specific gene targets are required to further understand this observation.</p><p>In contrast to the REV-ERBs and TR2, Liver Receptor Homolog-1 (LRH-1, NR5A2) is a constitutive transcriptional activator, binding DNA as a monomer to promote transcription (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B14" ref-type="bibr">14</xref>). The activity of LRH-1 was previously thought to be mainly under the control of co-regulators (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B81" ref-type="bibr">81</xref>, <xref rid="B82" ref-type="bibr">82</xref>, <xref rid="B83" ref-type="bibr">83</xref>); however potential endogenous ligands identified include phosphatidylinositols, in particular, phosphatidylinositol-3-phosphate (PIP<sub>3</sub>) (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B54" ref-type="bibr">54</xref>), small molecule agonists (<xref rid="B84" ref-type="bibr">84</xref>) and antagonists (<xref rid="B85" ref-type="bibr">85</xref>).</p><p>Low LRH-1 expression significantly correlated with increased DFS in Luminal B tumor patients (Table <xref ref-type="table" rid="T2">2</xref>, <italic>p</italic>&#x02009;=&#x02009;0.003). Additionally, a strong correlation with co-regulator expression in ER-negative breast tumors suggests that increased LRH-1 activity may correlate with predicted poorer outcome for those patients (<xref rid="B55" ref-type="bibr">55</xref>). The expression of LRH-1 in both ER-positive and ER-negative tumors indicate that more functional evidence is require to determine its contribution in these varying tumor contexts. There is strong functional evidence linking LRH-1 to estrogen-regulated pathways in breast cancer tumor and associated stromal cell types [reviewed in Ref. (<xref rid="B86" ref-type="bibr">86</xref>)].</p><p>LRH-1 stimulates transcription of the aromatase gene, thereby promoting estrogen synthesis within CAFs (<xref rid="B87" ref-type="bibr">87</xref>&#x02013;<xref rid="B89" ref-type="bibr">89</xref>). Given this strong association with tumor-associated estrogen production, most functional studies have been directed toward understanding the interplay between LRH-1 and estrogen-dependent proliferation pathways within breast tumors. While LRH-1 expression itself is under estrogen regulation, LRH-1 in a positive feedback manner induces estrogen-mediated cell proliferation (<xref rid="B90" ref-type="bibr">90</xref>). This is primarily via the co-operative regulation of gene-transcription of ER&#x003b1; and LRH-1 target genes (<xref rid="B91" ref-type="bibr">91</xref>&#x02013;<xref rid="B93" ref-type="bibr">93</xref>). Both ER&#x003b1; and LRH-1 directly stimulate the transcription of one another, adding to the close functional relationship between the two NRs (<xref rid="B90" ref-type="bibr">90</xref>, <xref rid="B94" ref-type="bibr">94</xref>). There are five transcript variants of LRH-1 that give rise to protein isoforms of three different sizes. There is some evidence that transcript variant four may be the active LRH-1 isoform in ER-positive breast cancer cells (<xref rid="B94" ref-type="bibr">94</xref>).</p><p>LRH-1 expression is detectable in both ER-positive and negative tumors (<xref rid="B95" ref-type="bibr">95</xref>). Despite low mRNA, LRH-1 protein levels are readily detected in ER-negative breast cancer cell lines and tumor tissue (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B95" ref-type="bibr">95</xref>&#x02013;<xref rid="B97" ref-type="bibr">97</xref>) and this discrepancy is partly explained by increased transcript stability in ER-negative tumor cells (<xref rid="B97" ref-type="bibr">97</xref>). Knockdown of LRH-1 expression with shRNA constructs in ER-negative cells reduced cell migration and invasion in ER-negative breast cancer cells (<xref rid="B98" ref-type="bibr">98</xref>). The functional importance of LRH-1 in ER-negative cells and the ability of LRH-1 to regulate cell proliferation gene expression in endocrine-resistant breast cancer cells (<xref rid="B91" ref-type="bibr">91</xref>) as well as in the presence of SERDs (<xref rid="B92" ref-type="bibr">92</xref>) suggests a possible role in promoting tumor-aggressiveness. Given the breadth of knowledge on the tumor promoting effects of LRH-1 in various cancers, LRH-1 is a strong candidate as a therapeutic target. However, there is a need to demonstrate its contribution to mammary tumor initiation and formation using <italic>in vivo</italic> mouse models.</p><p>As age is the most common risk factor in breast cancer, it is interesting to note that the expression of RAR-related orphan receptor &#x003b2; (ROR&#x003b2;, also known as NR1F2) is greater in the postmenopausal breast compared to premenopausal tissue. However, its expression is significantly downregulated in ER-negative breast cancer implicating a potential role in the early stages of tumor growth (<xref rid="B57" ref-type="bibr">57</xref>). Above median expression of ROR&#x003b2; is correlated with greater DFS rates in patients with Luminal B cancers (Table <xref ref-type="table" rid="T2">2</xref>, <italic>p</italic>&#x02009;=&#x02009;0.011). Although its function is unclear, the ligands for ROR&#x003b2; may provide additional functional evidence of its roles in breast cancer cells.</p></sec><sec id="S3-3"><title>ONRs associated with lymph node-positive breast cancer</title><p>Lymph node status is one of the most important predictors of breast cancer recurrence and survival. Data from the Surveillance, Epidemiology, and End Results (SEER) Program shows that women with lymph node negative tumors have a better prognosis compared to those with tumors in the lymph nodes.</p><p>In addition to overall DFS for all breast cancer cases, low ERR&#x003b1; and high NURR1 expression was associated with improved survival in patients with lymph node positive tumors (<italic>p</italic>&#x02009;=&#x02009;0.019 and <italic>p</italic>&#x02009;=&#x02009;0.007, respectively, Table <xref ref-type="table" rid="T2">2</xref>). Structurally and functionally related to the ERs, ERR&#x003b1; (Estrogen-related receptor (ERR) alpha, also known as NR3B1) over-expression is associated with a poorer outcome in patients with ER-negative breast cancer (<xref rid="B99" ref-type="bibr">99</xref>). Functional <italic>in vitro</italic> studies in breast cancer cell lines show that the suppression of ERR&#x003b1; inhibits cellular proliferation and migration (<xref rid="B100" ref-type="bibr">100</xref>). Expression of ERR&#x003b1; positively correlates with HER2 status in breast tumors and ERR&#x003b1; transcriptional activity is positively modulated by EGFR/HER2 signaling in breast cancer cells. This suggests a role for ERR&#x003b1; in mediating the transition from ER-positive luminal toward more aggressive HER2-expressing tumor subtype (<xref rid="B101" ref-type="bibr">101</xref>, <xref rid="B102" ref-type="bibr">102</xref>).</p><p>NURR1 (the NR-related 1 protein, also known as NR4A2), nerve growth factor I B (NGFIB, also known as Nur77 or NR4A1), and the neuron-derived orphan receptor 1 (NOR1, NR4A3) together constitute the NR4A subfamily of NRs (<xref rid="B103" ref-type="bibr">103</xref>&#x02013;<xref rid="B105" ref-type="bibr">105</xref>). No endogenous ligands have been identified for these ONRs and their ability to transactivate genes appears to be constitutive. The NR4A receptors are however targeted by several hormones and xenobiotic compounds that affect the expression and/or activity of these stress early response genes (Table <xref ref-type="table" rid="T1">1</xref>) (<xref rid="B106" ref-type="bibr">106</xref>). A recent study profiling all NRs in ER-positive and ER-negative breast tumors revealed that while most NR mRNA levels were significantly lower in breast cancer versus normal tissue, the expression of all of the NR4A family members (Nur77, NURR1, and NOR1) were significantly up-regulated in ER-positive breast cancer (<xref rid="B57" ref-type="bibr">57</xref>). Additionally in ER-negative breast tumors, when compared to normal breast tissue, NUR77 and NOR-1, together with EAR2, were found to have significantly increased (<xref rid="B57" ref-type="bibr">57</xref>).</p><p>In primary tumors, protein levels of NURR1 are inversely correlated with lymph node metastasis (<xref rid="B107" ref-type="bibr">107</xref>). This observation is mirrored in our analysis with the BreastMark dataset showing increased NURR1 mRNA expression is significantly correlated with increased survival in lymph node positive breast cancer. Data analysis from BreastMark and Kaplan&#x02013;Meier Plotter indicate above median expression of NURR1 mRNA is associated with better prognosis and RFS in all breast cancer patients (<xref rid="B107" ref-type="bibr">107</xref>). However, functional <italic>in vivo</italic> experiments indicate the contrary. When NURR1 expression is knocked down by shRNA, growth of xenografts of highly invasive MDA-MB-231 and MDA-MB-468 breast cancer cells in athymic nude mice is significantly attenuated (<xref rid="B107" ref-type="bibr">107</xref>). Interestingly, high cytoplasmic expression of NURR1 is significantly correlated with advanced pathologic stage and higher tumor grade of bladder tumors as well as an increased number of distant metastases and decreased recurrence free survival (<xref rid="B108" ref-type="bibr">108</xref>). Thus, not only the expression level of NURR1 but the sub-cellular localization in which it is expressed may be of importance in its contribution toward tumor growth and metastatic potential.</p><p>Increased expression of NOR1 is correlated with better clinical outcomes in patients with lymph node positive tumors and ER-positive tumors (<italic>p</italic>&#x02009;=&#x02009;0.003 and <italic>p</italic>&#x02009;=&#x02009;0.014 Tables <xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>, respectively). Little is known about the actions of NOR1 in breast cancer, however in the ER-positive breast cancer cell line MCF7, NOR1 mRNA is up-regulated by a pro-apoptotic compound A23187 (<xref rid="B109" ref-type="bibr">109</xref>), shown to cause apoptotic cell death, suggesting a possible role in tumor cell apoptosis. NOR1 and NUR77 are thought to form heterodimers with NR retinoid X receptor RXR to modulate retinoic acid (RA) signaling (<xref rid="B110" ref-type="bibr">110</xref>, <xref rid="B111" ref-type="bibr">111</xref>). Additionally in a positive feedback loop, RAs are involved in the positive regulation of NOR1 and NURR1 and the downregulation of NUR77 in breast cancer cells (<xref rid="B112" ref-type="bibr">112</xref>) correlating to decrease cell proliferation (<xref rid="B113" ref-type="bibr">113</xref>&#x02013;<xref rid="B115" ref-type="bibr">115</xref>). Taken together these studies indicate that the NR4A family members may exert multiple functions in cancer, through their genomic functions in promoting tumor growth and survival, and, paradoxically, through non-genomic functions that may potentially exert tumor suppression by induction of apoptosis.</p><p>We observed an association of increased COUP-TFII expression with improved survival in patients with lymph node-positive tumors (Table <xref ref-type="table" rid="T2">2</xref>, <italic>p</italic>&#x02009;=&#x02009;0.009). The mRNA levels of the COUP transcription factors COUP-TFI (NR2F1) and COUP-TFII (NR2F2) were reported to be significantly decreased in both ER-positive and ER-negative breast cancer tissue compared to normal breast (<xref rid="B57" ref-type="bibr">57</xref>). COUP-TFII mRNA showed a discriminating role in the classification of breast cancer grades as it was more highly expressed in better-differentiated, lower-grade lesions (<xref rid="B57" ref-type="bibr">57</xref>). COUP-TFII was, in addition to the NR members TR&#x003b2;, MR and PPAR&#x003b3;, reported to be a predictor of improved metastasis-free survival in tamoxifen-treated patients after adjustment for expression of ER&#x003b1; (<xref rid="B57" ref-type="bibr">57</xref>).</p><p>However, previously the amounts of protein of both these receptors have been reported to be higher in human breast cancer tissue than normal breast (<xref rid="B116" ref-type="bibr">116</xref>, <xref rid="B117" ref-type="bibr">117</xref>). While the results are uncertain for COUP-TFI as it was only examined in a very small set of samples (<xref rid="B116" ref-type="bibr">116</xref>), COUP-TFII protein expression has been examined in a larger cohort of human breast cancers (<xref rid="B117" ref-type="bibr">117</xref>). Of 119 invasive ductal carcinoma of the breast, 59% stained positive for COUP-TFII in the nuclei of carcinoma cells (<xref rid="B117" ref-type="bibr">117</xref>). Higher nuclear expression of COUP-TFII was correlated with decreased disease-free and overall survival of the patient (<xref rid="B117" ref-type="bibr">117</xref>). Additionally, COUP-TFII was correlated to clinical stage (significantly higher expressed in stage IV tumors than stage I), histological grade (significantly higher expression with grade) and ER&#x003b1; status (significantly higher expressed in ER&#x003b1; positive than negative breast carcinomas) (<xref rid="B117" ref-type="bibr">117</xref>). Several groups have looked at the function of COUP-TFI and COUP-TFII in breast cancer cell lines. COUP-TFI may promote estrogen-independent transcriptional activity of ER&#x003b1; in breast cancer cells (<xref rid="B116" ref-type="bibr">116</xref>, <xref rid="B118" ref-type="bibr">118</xref>). Furthermore, COUP-TFI mediates its actions through CXCL12/CXCR4 signaling. The over-expression of COUP-TFI results in down-regulation of CXCL12 and up-regulation of CXCR4 expression, to promote motility of MCF-7 cells (<xref rid="B119" ref-type="bibr">119</xref>). Furthermore, COUP-TFI mRNA expression is significantly higher in grade 1 (but not in grade 2 or 3) tumors than in normal breast tissue and that CXCR4 mRNA is significantly higher in cancerous tissue than in normal breast tissue and its expression is increasing with tumor grade, whereas transcripts of CXCL12 was significantly decreased in all the tumor grades compared to normal tissues (<xref rid="B119" ref-type="bibr">119</xref>).</p></sec><sec id="S3-4"><title>ONRs associated with lymph node-negative breast cancer</title><p>Higher SHP, ERR&#x003b2; and GCNF expression were associated with improved survival in patients with lymph node-negative tumors (<italic>p</italic>&#x02009;=&#x02009;0.022, <italic>p</italic>&#x02009;=&#x02009;0.01, <italic>p</italic>&#x02009;=&#x02009;0.015, respectively, Table <xref ref-type="table" rid="T2">2</xref>). Like Dax-1 (NROB1), the other member of this subgroup, short heterodimer partner (SHP, also termed NROB2) lacks a DNA-binding domain (DBD) and represses the action of NRs, including ER&#x003b1; through direct interaction with the receptor (<xref rid="B120" ref-type="bibr">120</xref>). SHP has been shown to inhibit aromatase expression by repressing LRH-1 activity on the promoter II element of <italic>Cyp19</italic>, the gene encoding aromatase (<xref rid="B121" ref-type="bibr">121</xref>). The actions of SHP in the repression of ER, LRH-1 and other NRs illustrates the importance of assessing the expression profile of this ONR in relation to other NRs to gage NR functionality. Above median expression of SHP also correlated with increased DFS in the luminal B subtype (Table <xref ref-type="table" rid="T2">2</xref>, <italic>p</italic>&#x02009;=&#x02009;0.004). These findings indicate that SHP may have a protective function in breast cancers and may be specifically so in lymph node-negative and luminal B subtype tumors. The expression and further characterization of this ONR are important due to its interactions with a range of NRs; whether SHP binds preferentially to ONRs over other co-regulators would also assist in defining its contribution to ONR-dependent actions in the cancer context.</p><p>Estrogen-related receptors are a subgroup of ONRs that have a strong homology with ER. We have previously discussed the roles of ERR&#x003b1; in lymph node positive tumors. Above median expression of ERR&#x003b1; is associated with greater survival in patients with lymph node-negative tumors. In other studies, the overexpression of ERR&#x003b2; has been correlated with improved prognosis and longer relapse-free survival in breast cancer patients, and its mRNA levels inversely correlated with tumor cells in S-phase in patient-derived tumor samples (<xref rid="B122" ref-type="bibr">122</xref>). The functions of ERRs are tightly related to ER-mediated actions in breast cancer cells mainly due to the high degree of structural similarity to one another and to ER (<xref rid="B123" ref-type="bibr">123</xref>, <xref rid="B124" ref-type="bibr">124</xref>), there is very little known about the details of ERR family members in this context. Recently though, in a detailed comparison of the ERRs on estradiol-stimulated ER transcription it was identified that it is only ERR&#x003b2; that co-localized into the nucleus with ER&#x003b1; and with fluorescence resonance energy transfer revealed that ERR&#x003b2; directly interacted with ER&#x003b1; to repress its transcriptional activity (<xref rid="B125" ref-type="bibr">125</xref>). The findings further suggest a unique inhibitory role for ERR&#x003b2; in estrogen-dependent cellular function such as cancer cell proliferation via the regulation of cell cycle progression.</p><p>Similarly above median expression of Germ Cell Nuclear Factor Receptor (GCNF) is correlated with improved patient outcomes compared to those with below median expression (Table <xref ref-type="table" rid="T2">2</xref>, <italic>p</italic>&#x02009;=&#x02009;0.015). Initially identified as exclusively expressed in germ cells (<xref rid="B126" ref-type="bibr">126</xref>), GCNF is well characterized for its importance in embryonic development in regulating neural development and gastrulation (<xref rid="B127" ref-type="bibr">127</xref>) and oocyte function (<xref rid="B128" ref-type="bibr">128</xref>). Its unlikely role in breast cancer is suggested from a recent analysis of Affymetrix, Illumina and RNAseq microarray data to perform gene enrichment analysis identified shared common promoter motifs for GNCF in TNBC samples (<xref rid="B129" ref-type="bibr">129</xref>).</p></sec></sec><sec id="S4"><title>ONRs in ER-Positive and ER-Negative Breast Cancer</title><p>The Kaplan&#x02013;Meier Plot analysis was used to assess ONR expression in relation to RFS in breast cancer patients; stratified to ER-positive and ER-negative tumors. Here, gene expression data and survival information of 1,809 patients have been collated from GEO (Affymetrix HGU133A and HGU133&#x02009;+&#x02009;2 microarrays) EGA and TCGA (<xref rid="B130" ref-type="bibr">130</xref>). Above median expression of 16 out of 24 ONRs was significantly correlated with increased RFS when analyzing all breast cancer patients in the database (Table <xref ref-type="table" rid="T3">3</xref>, <italic>n</italic>&#x02009;=&#x02009;3554). As an exception, lower expression of REV-ERB&#x003b2; was correlated with increased patient RFS (<italic>p</italic>&#x02009;=&#x02009;1.0e<sup>&#x02212;4</sup>). In ER-positive breast cancer, above median expression of five ONRs including ROR&#x003b3;, PNR, Nurr77, Nurr1 and NOR1 was associated with better RFS (<italic>p</italic>&#x02009;=&#x02009;0.002, <italic>p</italic>&#x02009;=&#x02009;0.0036, <italic>p</italic>&#x02009;=&#x02009;0.013, <italic>p</italic>&#x02009;=&#x02009;0.0054 and <italic>p</italic>&#x02009;=&#x02009;0.014, respectively, Table <xref ref-type="table" rid="T3">3</xref>). In ER-negative breast cancer patients, higher expression of Dax-1 and TLX, and lower COUP-TFII expression were found to significantly correlate with increased RFS of (<italic>p</italic>&#x02009;=&#x02009;0.0001, <italic>p</italic>&#x02009;=&#x02009;0.0008, and <italic>p</italic>&#x02009;=&#x02009;0.034, respectively, Table <xref ref-type="table" rid="T3">3</xref>). This pattern or &#x000ad;association with ER status may be important in identifying the &#x000ad;regulatory mechanisms via which these ONRs are expressed; whether these ONRs modify/enhance the responses to endocrine therapies directed at ER such as SERMs are yet to be delineated.</p></sec><sec id="S5"><title>Summary</title><p>The NR family of transcription factors plays diverse and important roles in development and the regulation of normal physiological functions in a tissue-specific manner. By understanding the contribution of ONRs in breast cancer subtypes, many novel mechanistic insights into tumor progression can be gleaned. From our data analysis, we observe complex expression patterns of various ONRs that could be selectively assessed in Luminal A, Luminal B, Lymph node positive and negative tumor types. Indeed within the specific subtype, the function of a particular ONR may possess a completely unique transcriptional imprint, therefore with varied effects on tumor proliferation and invasiveness; as is observed for AR, which can have pro- and anti-proliferative effects that is dependent on ER status of the breast cancer cell.</p><p>There is a lot that is unknown about ONRs in terms of their basic expression profile, mode of regulation of expression, cell subtype expression patterns, roles in normal mammary gland development processes, and transcriptional targets in the mammary gland and tumor scenarios. Our review attempted to identify &#x0201c;candidates&#x0201d; that were closely associated with breast cancer survival outcomes and whether molecular subtypes of breast cancer could be linked to ONR expression patterns. In addition to expression patterns, large-scale ChIP-seq experiments in well defined in breast cancer tissue samples and in <italic>in vivo</italic> tumor models will identify ONRs that are critical in this process. In addition, determining changes in ONR expression linked to key risk factors in breast cancer may also assist in understanding the mechanisms of this disease. The ligand-dependent actions of NRs provide extensive information that could potentially allow us to design new ligands for the ONRs in order to modulate their function. By the pharmacological targeting critical ONRs, we may in future identify effective therapies that could complement existing therapies in the treatment of breast cancer.</p></sec><sec id="S7"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><p>We acknowledge the support of Victorian Government&#x02019;s Opera-tional Infrastructure Support Program and the National Health and Medical Research Council of Australia Grants. ALC is supported by an NHMRC Career Development Award (ID 1062247).</p></ack><fn-group><fn id="fn1"><p><sup>1</sup><uri xlink:type="simple" xlink:href="http://www.kmplot.com">www.kmplot.com</uri></p></fn><fn id="fn2"><p><sup>2</sup><uri xlink:type="simple" xlink:href="http://glados.ucd.ie/BreastMark/index.html">http://glados.ucd.ie/BreastMark/index.html</uri></p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Dikshit</surname><given-names>R</given-names></name><name><surname>Eser</surname><given-names>S</given-names></name><name><surname>Mathers</surname><given-names>C</given-names></name><name><surname>Rebelo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012</article-title>. <source>Int J Cancer</source> (<year>2015</year>) <volume>136</volume>:<fpage>E359</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="doi">10.1002/ijc.29210</pub-id><?supplied-pmid 25220842?><pub-id pub-id-type="pmid">25220842</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Missmer</surname><given-names>SA</given-names></name><name><surname>Eliassen</surname><given-names>AH</given-names></name><name><surname>Barbieri</surname><given-names>RL</given-names></name><name><surname>Hankinson</surname><given-names>SE</given-names></name></person-group>. <article-title>Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women</article-title>. <source>J Natl Cancer Inst</source> (<year>2004</year>) <volume>96</volume>:<fpage>1856</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1093/jnci/djh336</pub-id><?supplied-pmid 15601642?><pub-id pub-id-type="pmid">15601642</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brodie</surname><given-names>AM</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name><name><surname>Coombes</surname><given-names>RC</given-names></name></person-group>
<article-title>Aromatase inhibitors as new endocrine therapy for breast cancer</article-title>. <source>Cancer Treat Res</source> (<year>1988</year>) <volume>39</volume>:<fpage>51</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1007/978-1-4613-1731-9_4</pub-id><pub-id pub-id-type="pmid">2908608</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katzenellenbogen</surname><given-names>BS</given-names></name><name><surname>Katzenellenbogen</surname><given-names>JA</given-names></name></person-group>. <article-title>Estrogen receptor transcription and transactivation: estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer</article-title>. <source>Breast Cancer Res</source> (<year>2000</year>) <volume>2</volume>:<fpage>335</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1186/bcr78</pub-id><?supplied-pmid 11250726?><pub-id pub-id-type="pmid">11250726</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>ER</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name></person-group>. <article-title>Aromatase and its inhibitors: significance for breast cancer therapy</article-title>. <source>Recent Prog Horm Res</source> (<year>2002</year>) <volume>57</volume>:<fpage>317</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="doi">10.1210/rp.57.1.317</pub-id><?supplied-pmid 12017550?><pub-id pub-id-type="pmid">12017550</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musgrove</surname><given-names>EA</given-names></name><name><surname>Sutherland</surname><given-names>RL</given-names></name></person-group>
<article-title>Biological determinants of endocrine resistance in breast cancer</article-title>. <source>Nat Rev Cancer</source> (<year>2009</year>) <volume>9</volume>:<fpage>631</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1038/nrc2713</pub-id><pub-id pub-id-type="pmid">19701242</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benoit</surname><given-names>G</given-names></name><name><surname>Cooney</surname><given-names>A</given-names></name><name><surname>Giguere</surname><given-names>V</given-names></name><name><surname>Ingraham</surname><given-names>H</given-names></name><name><surname>Lazar</surname><given-names>M</given-names></name><name><surname>Muscat</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>International union of pharmacology. LXVI. Orphan nuclear receptors</article-title>. <source>Pharmacol Rev</source> (<year>2006</year>) <volume>58</volume>:<fpage>798</fpage>&#x02013;<lpage>836</lpage>.<pub-id pub-id-type="doi">10.1124/pr.58.4.10</pub-id><?supplied-pmid 17132856?><pub-id pub-id-type="pmid">17132856</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>T</given-names></name></person-group>
<article-title>Nuclear receptor drug discovery</article-title>. <source>Curr Opin Chem Biol</source> (<year>2008</year>) <volume>12</volume>:<fpage>418</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1016/j.cbpa.2008.07.001</pub-id><pub-id pub-id-type="pmid">18662801</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Mei</surname><given-names>C</given-names></name><name><surname>Ercolani</surname><given-names>L</given-names></name><name><surname>Parodi</surname><given-names>C</given-names></name><name><surname>Veronesi</surname><given-names>M</given-names></name><name><surname>Vecchio</surname><given-names>CL</given-names></name><name><surname>Bottegoni</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Dual inhibition of REV-ERBbeta and autophagy as a novel pharmacological approach to induce cytotoxicity in cancer cells</article-title>. <source>Oncogene</source> (<year>2015</year>) <volume>34</volume>(<issue>20</issue>):<fpage>2597</fpage>&#x02013;<lpage>608</lpage>.<pub-id pub-id-type="doi">10.1038/onc.2014.203</pub-id><?supplied-pmid 25023698?><pub-id pub-id-type="pmid">25023698</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benoit</surname><given-names>G</given-names></name><name><surname>Malewicz</surname><given-names>M</given-names></name><name><surname>Perlmann</surname><given-names>T</given-names></name></person-group>. <article-title>Digging deep into the pockets of orphan nuclear receptors: insights from structural studies</article-title>. <source>Trends Cell Biol</source> (<year>2004</year>) <volume>14</volume>:<fpage>369</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="doi">10.1016/j.tcb.2004.05.007</pub-id><?supplied-pmid 15246430?><pub-id pub-id-type="pmid">15246430</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krylova</surname><given-names>IN</given-names></name><name><surname>Sablin</surname><given-names>EP</given-names></name><name><surname>Moore</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>RX</given-names></name><name><surname>Waitt</surname><given-names>GM</given-names></name><name><surname>MacKay</surname><given-names>JA</given-names></name><etal/></person-group>
<article-title>Structural analyses reveal phosphatidyl inositols as ligands for the NR5 orphan receptors SF-1 and LRH-1</article-title>. <source>Cell</source> (<year>2005</year>) <volume>120</volume>:<fpage>343</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2005.01.024</pub-id><?supplied-pmid 15707893?><pub-id pub-id-type="pmid">15707893</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Choi</surname><given-names>M</given-names></name><name><surname>Cavey</surname><given-names>G</given-names></name><name><surname>Daugherty</surname><given-names>J</given-names></name><name><surname>Suino</surname><given-names>K</given-names></name><name><surname>Kovach</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Crystallographic identification and functional characterization of phospholipids as ligands for the orphan nuclear receptor steroidogenic factor-1</article-title>. <source>Mol Cell</source> (<year>2005</year>) <volume>17</volume>:<fpage>491</fpage>&#x02013;<lpage>502</lpage>.<pub-id pub-id-type="doi">10.1016/j.molcel.2005.02.002</pub-id><?supplied-pmid 15721253?><pub-id pub-id-type="pmid">15721253</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lambert</surname><given-names>MH</given-names></name><name><surname>Xu</surname><given-names>HE</given-names></name></person-group>. <article-title>Activation of nuclear receptors: a perspective from structural genomics</article-title>. <source>Structure</source> (<year>2003</year>) <volume>11</volume>:<fpage>741</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/S0969-2126(03)00133-3</pub-id><?supplied-pmid 12842037?><pub-id pub-id-type="pmid">12842037</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sablin</surname><given-names>EP</given-names></name><name><surname>Krylova</surname><given-names>IN</given-names></name><name><surname>Fletterick</surname><given-names>RJ</given-names></name><name><surname>Ingraham</surname><given-names>HA</given-names></name></person-group>. <article-title>Structural basis for ligand-independent activation of the orphan nuclear receptor LRH-1</article-title>. <source>Mol Cell</source> (<year>2003</year>) <volume>11</volume>:<fpage>1575</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1016/S1097-2765(03)00236-3</pub-id><?supplied-pmid 12820970?><pub-id pub-id-type="pmid">12820970</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahusen</surname><given-names>T</given-names></name><name><surname>Henke</surname><given-names>RT</given-names></name><name><surname>Kagan</surname><given-names>BL</given-names></name><name><surname>Wellstein</surname><given-names>A</given-names></name><name><surname>Riegel</surname><given-names>AT</given-names></name></person-group>. <article-title>The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer</article-title>. <source>Breast Cancer Res Treat</source> (<year>2009</year>) <volume>116</volume>:<fpage>225</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="doi">10.1007/s10549-009-0405-2</pub-id><?supplied-pmid 19418218?><pub-id pub-id-type="pmid">19418218</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>AS</given-names></name><name><surname>Lahusen</surname><given-names>JT</given-names></name><name><surname>Chien</surname><given-names>CD</given-names></name><name><surname>Fereshteh</surname><given-names>MP</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Dakshanamurthy</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells</article-title>. <source>Mol Cell Biol</source> (<year>2008</year>) <volume>28</volume>:<fpage>6580</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="doi">10.1128/MCB.00118-08</pub-id><?supplied-pmid 18765637?><pub-id pub-id-type="pmid">18765637</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>MI</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><name><surname>Ye</surname><given-names>M</given-names></name><name><surname>Fontana</surname><given-names>JA</given-names></name><name><surname>Farhana</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of SRC homology 2 domain-containing protein tyrosine phosphatase-2 activity</article-title>. <source>J Med Chem</source> (<year>2008</year>) <volume>51</volume>:<fpage>5650</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1021/jm800456k</pub-id><?supplied-pmid 18759424?><pub-id pub-id-type="pmid">18759424</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>MI</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Ye</surname><given-names>M</given-names></name><name><surname>Fontana</surname><given-names>JA</given-names></name><name><surname>Farhana</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: effects of modifying its carboxylate group on apoptosis, proliferation, and protein-tyrosine phosphatase activity</article-title>. <source>J Med Chem</source> (<year>2007</year>) <volume>51</volume>(<issue>18</issue>):<fpage>2622</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="doi">10.1021/jm800456k</pub-id><?supplied-pmid 17489579?><pub-id pub-id-type="pmid">17489579</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farhana</surname><given-names>L</given-names></name><name><surname>Dawson</surname><given-names>MI</given-names></name><name><surname>Dannenberg</surname><given-names>JH</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Fontana</surname><given-names>JA</given-names></name></person-group>. <article-title>SHP and Sin3A expression are essential for adamantyl-substituted retinoid-related molecule-mediated nuclear factor-kappaB activation, c-Fos/c-Jun expression, and cellular apoptosis</article-title>. <source>Mol Cancer Ther</source> (<year>2009</year>) <volume>8</volume>:<fpage>1625</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-08-0964</pub-id><?supplied-pmid 19509248?><pub-id pub-id-type="pmid">19509248</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farhana</surname><given-names>L</given-names></name><name><surname>Dawson</surname><given-names>MI</given-names></name><name><surname>Leid</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>DD</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Adamantyl-substituted retinoid-related molecules bind small heterodimer partner and modulate the Sin3A repressor</article-title>. <source>Cancer Res</source> (<year>2007</year>) <volume>67</volume>:<fpage>318</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-2164</pub-id><?supplied-pmid 17210713?><pub-id pub-id-type="pmid">17210713</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kojetin</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Kamenecka</surname><given-names>TM</given-names></name><name><surname>Burris</surname><given-names>TP</given-names></name></person-group>. <article-title>Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB</article-title>. <source>ACS Chem Biol</source> (<year>2011</year>) <volume>6</volume>:<fpage>131</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1021/cb1002575</pub-id><?supplied-pmid 21043485?><pub-id pub-id-type="pmid">21043485</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>N</given-names></name><name><surname>Solt</surname><given-names>LA</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Rogers</surname><given-names>PM</given-names></name><name><surname>Bhattacharyya</surname><given-names>G</given-names></name><name><surname>Kamenecka</surname><given-names>TM</given-names></name><etal/></person-group>
<article-title>Regulation of adipogenesis by natural and synthetic REV-ERB ligands</article-title>. <source>Endocrinology</source> (<year>2010</year>) <volume>151</volume>:<fpage>3015</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1210/en.2009-0800</pub-id><?supplied-pmid 20427485?><pub-id pub-id-type="pmid">20427485</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raghuram</surname><given-names>S</given-names></name><name><surname>Stayrook</surname><given-names>KR</given-names></name><name><surname>Huang</surname><given-names>P</given-names></name><name><surname>Rogers</surname><given-names>PM</given-names></name><name><surname>Nosie</surname><given-names>AK</given-names></name><name><surname>McClure</surname><given-names>DB</given-names></name><etal/></person-group>
<article-title>Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta</article-title>. <source>Nat Struct Mol Biol</source> (<year>2007</year>) <volume>14</volume>:<fpage>1207</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1038/nsmb1344</pub-id><?supplied-pmid 18037887?><pub-id pub-id-type="pmid">18037887</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solt</surname><given-names>LA</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Banerjee</surname><given-names>S</given-names></name><name><surname>Hughes</surname><given-names>T</given-names></name><name><surname>Kojetin</surname><given-names>DJ</given-names></name><name><surname>Lundasen</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists</article-title>. <source>Nature</source> (<year>2012</year>) <volume>485</volume>:<fpage>62</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1038/nature11030</pub-id><?supplied-pmid 22460951?><pub-id pub-id-type="pmid">22460951</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>N</given-names></name><name><surname>Curtin</surname><given-names>JC</given-names></name><name><surname>Qatanani</surname><given-names>M</given-names></name><name><surname>Szwergold</surname><given-names>NR</given-names></name><name><surname>Reid</surname><given-names>RA</given-names></name><etal/></person-group>
<article-title>Rev-erbalpha, a heme sensor that coordinates metabolic and circadian pathways</article-title>. <source>Science</source> (<year>2007</year>) <volume>318</volume>:<fpage>1786</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1126/science.1150179</pub-id><?supplied-pmid 18006707?><pub-id pub-id-type="pmid">18006707</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kallen</surname><given-names>J</given-names></name><name><surname>Schlaeppi</surname><given-names>JM</given-names></name><name><surname>Bitsch</surname><given-names>F</given-names></name><name><surname>Delhon</surname><given-names>I</given-names></name><name><surname>Fournier</surname><given-names>B</given-names></name></person-group>. <article-title>Crystal structure of the human RORalpha ligand binding domain in complex with cholesterol sulfate at 2.2 A</article-title>. <source>J Biol Chem</source> (<year>2004</year>) <volume>279</volume>:<fpage>14033</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M400302200</pub-id><?supplied-pmid 14722075?><pub-id pub-id-type="pmid">14722075</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kallen</surname><given-names>JA</given-names></name><name><surname>Schlaeppi</surname><given-names>JM</given-names></name><name><surname>Bitsch</surname><given-names>F</given-names></name><name><surname>Geisse</surname><given-names>S</given-names></name><name><surname>Geiser</surname><given-names>M</given-names></name><name><surname>Delhon</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>X-ray structure of the hRORalpha LBD at 1.63 A: structural and functional data that cholesterol or a cholesterol derivative is the natural ligand of RORalpha</article-title>. <source>Structure</source> (<year>2002</year>) <volume>10</volume>:<fpage>1697</fpage>&#x02013;<lpage>707</lpage>.<pub-id pub-id-type="doi">10.1016/S0969-2126(02)00912-7</pub-id><?supplied-pmid 12467577?><pub-id pub-id-type="pmid">12467577</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>H</given-names></name><name><surname>Takeda</surname><given-names>Y</given-names></name><name><surname>Muromoto</surname><given-names>R</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Hirao</surname><given-names>T</given-names></name><name><surname>Takeuchi</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Isoflavones enhance interleukin-17 gene expression via retinoic acid receptor-related orphan receptors alpha and gamma</article-title>. <source>Toxicology</source> (<year>2015</year>) <volume>329</volume>:<fpage>32</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.tox.2015.01.007</pub-id><?supplied-pmid 25583575?><pub-id pub-id-type="pmid">25583575</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stehlin-Gaon</surname><given-names>C</given-names></name><name><surname>Willmann</surname><given-names>D</given-names></name><name><surname>Zeyer</surname><given-names>D</given-names></name><name><surname>Sanglier</surname><given-names>S</given-names></name><name><surname>Van Dorsselaer</surname><given-names>A</given-names></name><name><surname>Renaud</surname><given-names>JP</given-names></name><etal/></person-group>
<article-title>All-trans retinoic acid is a ligand for the orphan nuclear receptor ROR beta</article-title>. <source>Nat Struct Biol</source> (<year>2003</year>) <volume>10</volume>:<fpage>820</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1038/nsb979</pub-id><?supplied-pmid 12958591?><pub-id pub-id-type="pmid">12958591</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hertz</surname><given-names>R</given-names></name><name><surname>Magenheim</surname><given-names>J</given-names></name><name><surname>Berman</surname><given-names>I</given-names></name><name><surname>Bar-Tana</surname><given-names>J</given-names></name></person-group>. <article-title>Fatty acyl-CoA thioesters are ligands of hepatic nuclear factor-4alpha</article-title>. <source>Nature</source> (<year>1998</year>) <volume>392</volume>:<fpage>512</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1038/33185</pub-id><?supplied-pmid 9548258?><pub-id pub-id-type="pmid">9548258</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wisely</surname><given-names>GB</given-names></name><name><surname>Miller</surname><given-names>AB</given-names></name><name><surname>Davis</surname><given-names>RG</given-names></name><name><surname>Thornquest</surname><given-names>AD</given-names><suffix>Jr</suffix></name><name><surname>Johnson</surname><given-names>R</given-names></name><name><surname>Spitzer</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids</article-title>. <source>Structure</source> (<year>2002</year>) <volume>10</volume>:<fpage>1225</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="doi">10.1016/S0969-2126(02)00829-8</pub-id><?supplied-pmid 12220494?><pub-id pub-id-type="pmid">12220494</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>XE</given-names></name><name><surname>Suino-Powell</surname><given-names>KM</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Chan</surname><given-names>CW</given-names></name><name><surname>Tanabe</surname><given-names>O</given-names></name><name><surname>Kruse</surname><given-names>SW</given-names></name><etal/></person-group>
<article-title>The orphan nuclear receptor TR4 is a vitamin A-activated nuclear receptor</article-title>. <source>J Biol Chem</source> (<year>2011</year>) <volume>286</volume>:<fpage>2877</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M110.168740</pub-id><?supplied-pmid 21068381?><pub-id pub-id-type="pmid">21068381</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benod</surname><given-names>C</given-names></name><name><surname>Villagomez</surname><given-names>R</given-names></name><name><surname>Filgueira</surname><given-names>CS</given-names></name><name><surname>Hwang</surname><given-names>PK</given-names></name><name><surname>Leonard</surname><given-names>PG</given-names></name><name><surname>Poncet-Montange</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>The human orphan nuclear receptor tailless (TLX, NR2E1) is druggable</article-title>. <source>PLoS One</source> (<year>2014</year>) <volume>9</volume>:<fpage>e99440</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0099440</pub-id><?supplied-pmid 24936658?><pub-id pub-id-type="pmid">24936658</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>Q</given-names></name><name><surname>Knapinska</surname><given-names>A</given-names></name><name><surname>Dobri</surname><given-names>N</given-names></name><name><surname>Madoux</surname><given-names>F</given-names></name><name><surname>Chase</surname><given-names>P</given-names></name><name><surname>Hodder</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>In pursuit of synthetic modulators for the orphan retina-specific nuclear receptor NR2E3</article-title>. <source>J Ocul Pharmacol Ther</source> (<year>2013</year>) <volume>29</volume>:<fpage>298</fpage>&#x02013;<lpage>309</lpage>.<pub-id pub-id-type="doi">10.1089/jop.2012.0135</pub-id><?supplied-pmid 23098562?><pub-id pub-id-type="pmid">23098562</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolkenberg</surname><given-names>SE</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Kapitskaya</surname><given-names>M</given-names></name><name><surname>Webber</surname><given-names>AL</given-names></name><name><surname>Petrukhin</surname><given-names>K</given-names></name><name><surname>Tang</surname><given-names>YS</given-names></name><etal/></person-group>
<article-title>Identification of potent agonists of photoreceptor-specific nuclear receptor (NR2E3) and preparation of a radioligand</article-title>. <source>Bioorg Med Chem Lett</source> (<year>2006</year>) <volume>16</volume>:<fpage>5001</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1016/j.bmcl.2006.07.056</pub-id><?supplied-pmid 16879962?><pub-id pub-id-type="pmid">16879962</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruse</surname><given-names>SW</given-names></name><name><surname>Suino-Powell</surname><given-names>K</given-names></name><name><surname>Zhou</surname><given-names>XE</given-names></name><name><surname>Kretschman</surname><given-names>JE</given-names></name><name><surname>Reynolds</surname><given-names>R</given-names></name><name><surname>Vonrhein</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Identification of COUP-TFII orphan nuclear receptor as a retinoic acid-activated receptor</article-title>. <source>PLoS Biol</source> (<year>2008</year>) <volume>6</volume>:<fpage>e227</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pbio.0060227</pub-id><?supplied-pmid 18798693?><pub-id pub-id-type="pmid">18798693</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coward</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Hull</surname><given-names>MV</given-names></name><name><surname>Lehmann</surname><given-names>JM</given-names></name></person-group>. <article-title>4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2001</year>) <volume>98</volume>:<fpage>8880</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.151244398</pub-id><?supplied-pmid 11447273?><pub-id pub-id-type="pmid">11447273</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suetsugi</surname><given-names>M</given-names></name><name><surname>Su</surname><given-names>L</given-names></name><name><surname>Karlsberg</surname><given-names>K</given-names></name><name><surname>Yuan</surname><given-names>YC</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name></person-group>. <article-title>Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors</article-title>. <source>Mol Cancer Res</source> (<year>2003</year>) <volume>1</volume>(<issue>13</issue>):<fpage>981</fpage>&#x02013;<lpage>91</lpage>.<?supplied-pmid 14638870?><pub-id pub-id-type="pmid">14638870</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name></person-group>. <article-title>Two organochlorine pesticides, toxaphene and chlordane, are antagonists for estrogen-related receptor alpha-1 orphan receptor</article-title>. <source>Cancer Res</source> (<year>1999</year>) <volume>59</volume>:<fpage>4519</fpage>&#x02013;<lpage>24</lpage>.<?supplied-pmid 10493499?><pub-id pub-id-type="pmid">10493499</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greschik</surname><given-names>H</given-names></name><name><surname>Flaig</surname><given-names>R</given-names></name><name><surname>Renaud</surname><given-names>JP</given-names></name><name><surname>Moras</surname><given-names>D</given-names></name></person-group>. <article-title>Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-&#x000ad;hydroxytamoxifen and determinants of selectivity</article-title>. <source>J Biol Chem</source> (<year>2004</year>) <volume>279</volume>:<fpage>33639</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M402195200</pub-id><?supplied-pmid 15161930?><pub-id pub-id-type="pmid">15161930</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chintharlapalli</surname><given-names>S</given-names></name><name><surname>Burghardt</surname><given-names>R</given-names></name><name><surname>Papineni</surname><given-names>S</given-names></name><name><surname>Ramaiah</surname><given-names>S</given-names></name><name><surname>Yoon</surname><given-names>K</given-names></name><name><surname>Safe</surname><given-names>S</given-names></name></person-group>. <article-title>Activation of Nur77 by selected 1,1-Bis(3&#x02019;-indolyl)-1-(p-substituted phenyl)methanes induces apoptosis through nuclear pathways</article-title>. <source>J Biol Chem</source> (<year>2005</year>) <volume>280</volume>:<fpage>24903</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M500107200</pub-id><?supplied-pmid 15871945?><pub-id pub-id-type="pmid">15871945</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>SD</given-names></name><name><surname>Lee</surname><given-names>SO</given-names></name><name><surname>Chintharlapalli</surname><given-names>S</given-names></name><name><surname>Abdelrahim</surname><given-names>M</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Yoon</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Activation of nerve growth factor-induced B alpha by methylene-&#x000ad;substituted diindolylmethanes in bladder cancer cells induces apoptosis and inhibits tumor growth</article-title>. <source>Mol Pharmacol</source> (<year>2010</year>) <volume>77</volume>:<fpage>396</fpage>&#x02013;<lpage>404</lpage>.<pub-id pub-id-type="doi">10.1124/mol.109.061143</pub-id><?supplied-pmid 20023005?><pub-id pub-id-type="pmid">20023005</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>SD</given-names></name><name><surname>Lei</surname><given-names>P</given-names></name><name><surname>Abdelrahim</surname><given-names>M</given-names></name><name><surname>Yoon</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>1,1-bis(3&#x02019;-indolyl)-1-(p-methoxyphenyl)methane activates Nur77-independent proapoptotic responses in colon cancer cells</article-title>. <source>Mol Carcinog</source> (<year>2008</year>) <volume>47</volume>:<fpage>252</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1002/mc.20378</pub-id><?supplied-pmid 17957723?><pub-id pub-id-type="pmid">17957723</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>SD</given-names></name><name><surname>Yoon</surname><given-names>K</given-names></name><name><surname>Chintharlapalli</surname><given-names>S</given-names></name><name><surname>Abdelrahim</surname><given-names>M</given-names></name><name><surname>Lei</surname><given-names>P</given-names></name><name><surname>Hamilton</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Nur77 agonists induce proapoptotic genes and responses in colon cancer cells through nuclear receptor-dependent and nuclear receptor-independent pathways</article-title>. <source>Cancer Res</source> (<year>2007</year>) <volume>67</volume>:<fpage>674</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-2907</pub-id><?supplied-pmid 17234778?><pub-id pub-id-type="pmid">17234778</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SO</given-names></name><name><surname>Abdelrahim</surname><given-names>M</given-names></name><name><surname>Yoon</surname><given-names>K</given-names></name><name><surname>Chintharlapalli</surname><given-names>S</given-names></name><name><surname>Papineni</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Inactivation of the orphan nuclear receptor TR3/Nur77 inhibits pancreatic cancer cell and tumor growth</article-title>. <source>Cancer Res</source> (<year>2010</year>) <volume>70</volume>:<fpage>6824</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1992</pub-id><?supplied-pmid 20660371?><pub-id pub-id-type="pmid">20660371</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>JJ</given-names></name><name><surname>Zeng</surname><given-names>HN</given-names></name><name><surname>Zhang</surname><given-names>LR</given-names></name><name><surname>Zhan</surname><given-names>YY</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>A unique pharmacophore for activation of the nuclear orphan receptor Nur77 in vivo and in vitro</article-title>. <source>Cancer Res</source> (<year>2010</year>) <volume>70</volume>:<fpage>3628</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-3160</pub-id><?supplied-pmid 20388790?><pub-id pub-id-type="pmid">20388790</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhan</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Cytosporone B is an agonist for nuclear orphan receptor Nur77</article-title>. <source>Nat Chem Biol</source> (<year>2008</year>) <volume>4</volume>:<fpage>548</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="doi">10.1038/nchembio.106</pub-id><?supplied-pmid 18690216?><pub-id pub-id-type="pmid">18690216</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubois</surname><given-names>C</given-names></name><name><surname>Hengerer</surname><given-names>B</given-names></name><name><surname>Mattes</surname><given-names>H</given-names></name></person-group>
<article-title>Identification of a potent agonist of the orphan nuclear receptor Nurr1</article-title>. <source>ChemMedChem</source> (<year>2006</year>) <volume>1</volume>:<fpage>955</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1002/cmdc.200600078</pub-id><pub-id pub-id-type="pmid">16952138</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hintermann</surname><given-names>S</given-names></name><name><surname>Chiesi</surname><given-names>M</given-names></name><name><surname>von Krosigk</surname><given-names>U</given-names></name><name><surname>Mathe</surname><given-names>D</given-names></name><name><surname>Felber</surname><given-names>R</given-names></name><name><surname>Hengerer</surname><given-names>B</given-names></name></person-group>. <article-title>Identification of a series of highly potent activators of the Nurr1 signaling pathway</article-title>. <source>Bioorg Med Chem Lett</source> (<year>2007</year>) <volume>17</volume>:<fpage>193</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.bmcl.2006.09.062</pub-id><?supplied-pmid 17035009?><pub-id pub-id-type="pmid">17035009</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inamoto</surname><given-names>T</given-names></name><name><surname>Papineni</surname><given-names>S</given-names></name><name><surname>Chintharlapalli</surname><given-names>S</given-names></name><name><surname>Cho</surname><given-names>SD</given-names></name><name><surname>Safe</surname><given-names>S</given-names></name><name><surname>Kamat</surname><given-names>AM</given-names></name></person-group>. <article-title>1,1-Bis(3&#x02019;-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth</article-title>. <source>Mol Cancer Ther</source> (<year>2008</year>) <volume>7</volume>:<fpage>3825</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-08-0730</pub-id><?supplied-pmid 19074857?><pub-id pub-id-type="pmid">19074857</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ordentlich</surname><given-names>P</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Heyman</surname><given-names>RA</given-names></name></person-group>. <article-title>Identification of the antineoplastic agent 6-mercaptopurine as an activator of the orphan nuclear hormone receptor Nurr1</article-title>. <source>J Biol Chem</source> (<year>2003</year>) <volume>278</volume>:<fpage>24791</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M302167200</pub-id><?supplied-pmid 12709433?><pub-id pub-id-type="pmid">12709433</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kagaya</surname><given-names>S</given-names></name><name><surname>Ohkura</surname><given-names>N</given-names></name><name><surname>Tsukada</surname><given-names>T</given-names></name><name><surname>Miyagawa</surname><given-names>M</given-names></name><name><surname>Sugita</surname><given-names>Y</given-names></name><name><surname>Tsujimoto</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Prostaglandin A2 acts as a transactivator for NOR1 (NR4A3) within the nuclear receptor superfamily</article-title>. <source>Biol Pharm Bull</source> (<year>2005</year>) <volume>28</volume>:<fpage>1603</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1248/bpb.28.1603</pub-id><?supplied-pmid 16141523?><pub-id pub-id-type="pmid">16141523</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wansa</surname><given-names>KD</given-names></name><name><surname>Harris</surname><given-names>JM</given-names></name><name><surname>Yan</surname><given-names>G</given-names></name><name><surname>Ordentlich</surname><given-names>P</given-names></name><name><surname>Muscat</surname><given-names>GE</given-names></name></person-group>. <article-title>The AF-1 domain of the orphan nuclear receptor NOR-1 mediates trans-activation, coactivator recruitment, and activation by the purine anti-metabolite 6-mercaptopurine</article-title>. <source>J Biol Chem</source> (<year>2003</year>) <volume>278</volume>:<fpage>24776</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M300088200</pub-id><?supplied-pmid 12709428?><pub-id pub-id-type="pmid">12709428</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortlund</surname><given-names>EA</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Solomon</surname><given-names>IH</given-names></name><name><surname>Hager</surname><given-names>JM</given-names></name><name><surname>Safi</surname><given-names>R</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Modulation of human nuclear receptor LRH-1 activity by phospholipids and SHP</article-title>. <source>Nat Struct Mol Biol</source> (<year>2005</year>) <volume>12</volume>:<fpage>357</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1038/nsmb910</pub-id><?supplied-pmid 15723037?><pub-id pub-id-type="pmid">15723037</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doan</surname><given-names>TB</given-names></name><name><surname>Eriksson</surname><given-names>NA</given-names></name><name><surname>Graham</surname><given-names>D</given-names></name><name><surname>Funder</surname><given-names>JW</given-names></name><name><surname>Simpson</surname><given-names>ER</given-names></name><name><surname>Kuczek</surname><given-names>ES</given-names></name><etal/></person-group>
<article-title>Breast cancer prognosis predicted by nuclear receptor-coregulator networks</article-title>. <source>Mol Oncol</source> (<year>2014</year>) <volume>8</volume>:<fpage>998</fpage>&#x02013;<lpage>1013</lpage>.<pub-id pub-id-type="doi">10.1016/j.molonc.2014.03.017</pub-id><?supplied-pmid 24785096?><pub-id pub-id-type="pmid">24785096</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knower</surname><given-names>KC</given-names></name><name><surname>Chand</surname><given-names>AL</given-names></name><name><surname>Eriksson</surname><given-names>N</given-names></name><name><surname>Takagi</surname><given-names>K</given-names></name><name><surname>Miki</surname><given-names>Y</given-names></name><name><surname>Sasano</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Distinct nuclear receptor expression in stroma adjacent to breast tumors</article-title>. <source>Breast Cancer Res Treat</source> (<year>2013</year>) <volume>142</volume>:<fpage>211</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1007/s10549-013-2716-6</pub-id><?supplied-pmid 24122391?><pub-id pub-id-type="pmid">24122391</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muscat</surname><given-names>GE</given-names></name><name><surname>Eriksson</surname><given-names>NA</given-names></name><name><surname>Byth</surname><given-names>K</given-names></name><name><surname>Loi</surname><given-names>S</given-names></name><name><surname>Graham</surname><given-names>D</given-names></name><name><surname>Jindal</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer</article-title>. <source>Mol Endocrinol</source> (<year>2013</year>) <volume>27</volume>:<fpage>350</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1210/me.2012-1265</pub-id><?supplied-pmid 23292282?><pub-id pub-id-type="pmid">23292282</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Sorlie</surname><given-names>T</given-names></name><name><surname>Eisen</surname><given-names>MB</given-names></name><name><surname>van de Rijn</surname><given-names>M</given-names></name><name><surname>Jeffrey</surname><given-names>SS</given-names></name><name><surname>Rees</surname><given-names>CA</given-names></name><etal/></person-group>
<article-title>Molecular portraits of human breast tumours</article-title>. <source>Nature</source> (<year>2000</year>) <volume>406</volume>:<fpage>747</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1038/35021093</pub-id><pub-id pub-id-type="pmid">10963602</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorlie</surname><given-names>T</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Aas</surname><given-names>T</given-names></name><name><surname>Geisler</surname><given-names>S</given-names></name><name><surname>Johnsen</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2001</year>) <volume>98</volume>:<fpage>10869</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.191367098</pub-id><?supplied-pmid 11553815?><pub-id pub-id-type="pmid">11553815</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorlie</surname><given-names>T</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Parker</surname><given-names>J</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>Marron</surname><given-names>JS</given-names></name><name><surname>Nobel</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Repeated observation of breast tumor subtypes in independent gene expression data sets</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2003</year>) <volume>100</volume>:<fpage>8418</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0932692100</pub-id><?supplied-pmid 12829800?><pub-id pub-id-type="pmid">12829800</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van &#x02018;t Veer</surname><given-names>LJ</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name><name><surname>van de Vijver</surname><given-names>MJ</given-names></name><name><surname>He</surname><given-names>YD</given-names></name><name><surname>Hart</surname><given-names>AA</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Expression profiling predicts outcome in breast cancer</article-title>. <source>Breast Cancer Res</source> (<year>2003</year>) <volume>5</volume>:<fpage>57</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1186/bcr716</pub-id><pub-id pub-id-type="pmid">12559048</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Vijver</surname><given-names>MJ</given-names></name><name><surname>He</surname><given-names>YD</given-names></name><name><surname>van&#x02019;t Veer</surname><given-names>LJ</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name><name><surname>Hart</surname><given-names>AA</given-names></name><name><surname>Voskuil</surname><given-names>DW</given-names></name><etal/></person-group>
<article-title>A gene-expression signature as a predictor of survival in breast cancer</article-title>. <source>N Engl J Med</source> (<year>2002</year>) <volume>347</volume>:<fpage>1999</fpage>&#x02013;<lpage>2009</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMoa021967</pub-id><pub-id pub-id-type="pmid">12490681</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badve</surname><given-names>S</given-names></name><name><surname>Turbin</surname><given-names>D</given-names></name><name><surname>Thorat</surname><given-names>MA</given-names></name><name><surname>Morimiya</surname><given-names>A</given-names></name><name><surname>Nielsen</surname><given-names>TO</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><etal/></person-group>
<article-title>FOXA1 expression in breast cancer &#x02013; correlation with luminal subtype A and survival</article-title>. <source>Clin Cancer Res</source> (<year>2007</year>) <volume>13</volume>:<fpage>4415</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-0122</pub-id><?supplied-pmid 17671124?><pub-id pub-id-type="pmid">17671124</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camp</surname><given-names>JT</given-names></name><name><surname>Elloumi</surname><given-names>F</given-names></name><name><surname>Roman-Perez</surname><given-names>E</given-names></name><name><surname>Rein</surname><given-names>J</given-names></name><name><surname>Stewart</surname><given-names>DA</given-names></name><name><surname>Harrell</surname><given-names>JC</given-names></name><etal/></person-group>
<article-title>Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers</article-title>. <source>Mol Cancer Res</source> (<year>2011</year>) <volume>9</volume>:<fpage>3</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1158/1541-7786.MCR-10-0372</pub-id><?supplied-pmid 21131600?><pub-id pub-id-type="pmid">21131600</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheang</surname><given-names>MC</given-names></name><name><surname>Chia</surname><given-names>SK</given-names></name><name><surname>Voduc</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>D</given-names></name><name><surname>Leung</surname><given-names>S</given-names></name><name><surname>Snider</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer</article-title>. <source>J Natl Cancer Inst</source> (<year>2009</year>) <volume>101</volume>:<fpage>736</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1093/jnci/djp082</pub-id><pub-id pub-id-type="pmid">19436038</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatza</surname><given-names>ML</given-names></name><name><surname>Silva</surname><given-names>GO</given-names></name><name><surname>Parker</surname><given-names>JS</given-names></name><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name></person-group>. <article-title>An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer</article-title>. <source>Nat Genet</source> (<year>2014</year>) <volume>46</volume>(<issue>10</issue>):<fpage>1051</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1038/ng.3073</pub-id><?supplied-pmid 25151356?><pub-id pub-id-type="pmid">25151356</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gyorffy</surname><given-names>B</given-names></name><name><surname>Schafer</surname><given-names>R</given-names></name></person-group>. <article-title>Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients</article-title>. <source>Breast Cancer Res Treat</source> (<year>2009</year>) <volume>118</volume>:<fpage>433</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1007/s10549-008-0242-8</pub-id><?supplied-pmid 19052860?><pub-id pub-id-type="pmid">19052860</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madden</surname><given-names>SF</given-names></name><name><surname>Clarke</surname><given-names>C</given-names></name><name><surname>Gaule</surname><given-names>P</given-names></name><name><surname>Aherne</surname><given-names>ST</given-names></name><name><surname>O&#x02019;Donovan</surname><given-names>N</given-names></name><name><surname>Clynes</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome</article-title>. <source>Breast Cancer Res</source> (<year>2013</year>) <volume>15</volume>:<fpage>R52</fpage>.<pub-id pub-id-type="doi">10.1186/bcr3444</pub-id><?supplied-pmid 23820017?><pub-id pub-id-type="pmid">23820017</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ning</surname><given-names>BF</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>C</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Hepatocyte nuclear factor 4 alpha suppresses the development of hepatocellular carcinoma</article-title>. <source>Cancer Res</source> (<year>2010</year>) <volume>70</volume>:<fpage>7640</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0824</pub-id><?supplied-pmid 20876809?><pub-id pub-id-type="pmid">20876809</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reznik</surname><given-names>E</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name></person-group>. <article-title>Extensive decoupling of metabolic genes in cancer</article-title>. <source>PLoS Comput Biol</source> (<year>2015</year>) <volume>11</volume>:<fpage>e1004176</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pcbi.1004176</pub-id><?supplied-pmid 25961905?><pub-id pub-id-type="pmid">25961905</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kummer</surname><given-names>MP</given-names></name><name><surname>Hammerschmidt</surname><given-names>T</given-names></name><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Terwel</surname><given-names>D</given-names></name><name><surname>Eichele</surname><given-names>G</given-names></name><name><surname>Witten</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Ear2 deletion causes early memory and learning deficits in APP/PS1 mice</article-title>. <source>J Neurosci</source> (<year>2014</year>) <volume>34</volume>:<fpage>8845</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4027-13.2014</pub-id><?supplied-pmid 24966384?><pub-id pub-id-type="pmid">24966384</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Sigmund</surname><given-names>CD</given-names></name></person-group>. <article-title>Identification of a nuclear orphan receptor (Ear2) as a negative regulator of renin gene transcription</article-title>. <source>Circ Res</source> (<year>2003</year>) <volume>92</volume>:<fpage>1033</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1161/01.RES.0000071355.82009.43</pub-id><?supplied-pmid 12690040?><pub-id pub-id-type="pmid">12690040</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warnecke</surname><given-names>M</given-names></name><name><surname>Oster</surname><given-names>H</given-names></name><name><surname>Revelli</surname><given-names>JP</given-names></name><name><surname>Alvarez-Bolado</surname><given-names>G</given-names></name><name><surname>Eichele</surname><given-names>G</given-names></name></person-group>. <article-title>Abnormal development of the locus coeruleus in Ear2(Nr2f6)-deficient mice impairs the functionality of the forebrain clock and affects nociception</article-title>. <source>Genes Dev</source> (<year>2005</year>) <volume>19</volume>:<fpage>614</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1101/gad.317905</pub-id><?supplied-pmid 15741322?><pub-id pub-id-type="pmid">15741322</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Dufau</surname><given-names>ML</given-names></name></person-group>. <article-title>EAR2 and EAR3/COUP-TFI regulate transcription of the rat LH receptor</article-title>. <source>Mol Endocrinol</source> (<year>2001</year>) <volume>15</volume>:<fpage>1891</fpage>&#x02013;<lpage>905</lpage>.<pub-id pub-id-type="doi">10.1210/mend.15.11.0720</pub-id><?supplied-pmid 11682620?><pub-id pub-id-type="pmid">11682620</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Sasano</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Gurates</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Regulation of aromatase P450 expression in endometriotic and endometrial stromal cells by CCAAT/enhancer binding proteins (C/EBPs): decreased C/EBPbeta in endometriosis is associated with overexpression of aromatase</article-title>. <source>J Clin Endocrinol Metab</source> (<year>2002</year>) <volume>87</volume>:<fpage>2336</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1210/jc.87.5.2336</pub-id><?supplied-pmid 11994385?><pub-id pub-id-type="pmid">11994385</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerhart-Hines</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>D</given-names></name><name><surname>Emmett</surname><given-names>MJ</given-names></name><name><surname>Everett</surname><given-names>LJ</given-names></name><name><surname>Loro</surname><given-names>E</given-names></name><name><surname>Briggs</surname><given-names>ER</given-names></name><etal/></person-group>
<article-title>The nuclear receptor Rev-erbalpha controls circadian thermogenic plasticity</article-title>. <source>Nature</source> (<year>2013</year>) <volume>503</volume>:<fpage>410</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1038/nature12642</pub-id><?supplied-pmid 24162845?><pub-id pub-id-type="pmid">24162845</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kourtidis</surname><given-names>A</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Carkner</surname><given-names>RD</given-names></name><name><surname>Eifert</surname><given-names>C</given-names></name><name><surname>Brosnan</surname><given-names>MJ</given-names></name><name><surname>Conklin</surname><given-names>DS</given-names></name></person-group>. <article-title>An RNA interference screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature</article-title>. <source>Cancer Res</source> (<year>2010</year>) <volume>70</volume>:<fpage>1783</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1550</pub-id><?supplied-pmid 20160030?><pub-id pub-id-type="pmid">20160030</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>YC</given-names></name><name><surname>Shyr</surname><given-names>CR</given-names></name><name><surname>Che</surname><given-names>W</given-names></name><name><surname>Mu</surname><given-names>XM</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name></person-group>. <article-title>Suppression of estrogen receptor-mediated transcription and cell growth by interaction with TR2 orphan receptor</article-title>. <source>J Biol Chem</source> (<year>2002</year>) <volume>277</volume>:<fpage>33571</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M203531200</pub-id><?supplied-pmid 12093804?><pub-id pub-id-type="pmid">12093804</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanabe</surname><given-names>O</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Campbell</surname><given-names>AD</given-names></name><name><surname>Kuroha</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>The TR2 and TR4 orphan nuclear receptors repress Gata1 transcription</article-title>. <source>Genes Dev</source> (<year>2007</year>) <volume>21</volume>:<fpage>2832</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1101/gad.1593307</pub-id><?supplied-pmid 17974920?><pub-id pub-id-type="pmid">17974920</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boidot</surname><given-names>R</given-names></name><name><surname>Vegran</surname><given-names>F</given-names></name><name><surname>Jacob</surname><given-names>D</given-names></name><name><surname>Chevrier</surname><given-names>S</given-names></name><name><surname>Cadouot</surname><given-names>M</given-names></name><name><surname>Feron</surname><given-names>O</given-names></name><etal/></person-group>
<article-title>The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism</article-title>. <source>Oncogene</source> (<year>2010</year>) <volume>29</volume>:<fpage>2577</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1038/onc.2009.525</pub-id><?supplied-pmid 20101202?><pub-id pub-id-type="pmid">20101202</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Kasahara</surname><given-names>M</given-names></name><name><surname>Yoshioka</surname><given-names>H</given-names></name><name><surname>Umesono</surname><given-names>K</given-names></name><name><surname>Morohashi</surname><given-names>K</given-names></name></person-group>
<article-title>LXXLL motifs in Dax-1 have target specificity for the orphan nuclear receptors Ad4BP/SF-1 and LRH-1</article-title>. <source>Endocr Res</source> (<year>2002</year>) <volume>28</volume>:<fpage>537</fpage><pub-id pub-id-type="doi">10.1081/ERC-120016835</pub-id><pub-id pub-id-type="pmid">12530660</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yazawa</surname><given-names>T</given-names></name><name><surname>Inaoka</surname><given-names>Y</given-names></name><name><surname>Okada</surname><given-names>R</given-names></name><name><surname>Mizutani</surname><given-names>T</given-names></name><name><surname>Yamazaki</surname><given-names>Y</given-names></name><name><surname>Usami</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>PPAR-gamma coactivator-1alpha regulates progesterone production in ovarian granulosa cells with SF-1 and LRH-1</article-title>. <source>Mol Endocrinol</source> (<year>2010</year>) <volume>24</volume>:<fpage>485</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="doi">10.1210/me.2009-0352</pub-id><?supplied-pmid 20133449?><pub-id pub-id-type="pmid">20133449</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Choi</surname><given-names>M</given-names></name><name><surname>Suino</surname><given-names>K</given-names></name><name><surname>Kovach</surname><given-names>A</given-names></name><name><surname>Daugherty</surname><given-names>J</given-names></name><name><surname>Kliewer</surname><given-names>SA</given-names></name><etal/></person-group>
<article-title>Structural and biochemical basis for selective repression of the orphan nuclear receptor liver receptor homolog 1 by small heterodimer partner</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2005</year>) <volume>102</volume>:<fpage>9505</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0501204102</pub-id><?supplied-pmid 15976031?><pub-id pub-id-type="pmid">15976031</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitby</surname><given-names>RJ</given-names></name><name><surname>Dixon</surname><given-names>S</given-names></name><name><surname>Maloney</surname><given-names>PR</given-names></name><name><surname>Delerive</surname><given-names>P</given-names></name><name><surname>Goodwin</surname><given-names>BJ</given-names></name><name><surname>Parks</surname><given-names>DJ</given-names></name><etal/></person-group>
<article-title>Identification of small molecule agonists of the orphan nuclear receptors liver receptor homolog-1 and steroidogenic factor-1</article-title>. <source>J Med Chem</source> (<year>2006</year>) <volume>49</volume>:<fpage>6652</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1021/jm060990k</pub-id><?supplied-pmid 17154495?><pub-id pub-id-type="pmid">17154495</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benod</surname><given-names>C</given-names></name><name><surname>Carlsson</surname><given-names>J</given-names></name><name><surname>Uthayaruban</surname><given-names>R</given-names></name><name><surname>Hwang</surname><given-names>P</given-names></name><name><surname>Irwin</surname><given-names>JJ</given-names></name><name><surname>Doak</surname><given-names>AK</given-names></name><etal/></person-group>
<article-title>Structure-based discovery of antagonists of nuclear receptor LRH-1</article-title>. <source>J Biol Chem</source> (<year>2013</year>) <volume>288</volume>:<fpage>19830</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M112.411686</pub-id><?supplied-pmid 23667258?><pub-id pub-id-type="pmid">23667258</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazarus</surname><given-names>KA</given-names></name><name><surname>Wijayakumara</surname><given-names>D</given-names></name><name><surname>Chand</surname><given-names>AL</given-names></name><name><surname>Simpson</surname><given-names>ER</given-names></name><name><surname>Clyne</surname><given-names>CD</given-names></name></person-group>. <article-title>Therapeutic potential of liver receptor homolog-1 modulators</article-title>. <source>J Steroid Biochem Mol Biol</source> (<year>2012</year>) <volume>130</volume>:<fpage>138</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="doi">10.1016/j.jsbmb.2011.12.017</pub-id><?supplied-pmid 22266285?><pub-id pub-id-type="pmid">22266285</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouchard</surname><given-names>MF</given-names></name><name><surname>Taniguchi</surname><given-names>H</given-names></name><name><surname>Viger</surname><given-names>RS</given-names></name></person-group>. <article-title>Protein kinase A-dependent synergism between GATA factors and the nuclear receptor, liver receptor homolog-1, regulates human aromatase (CYP19) PII promoter activity in breast cancer cells</article-title>. <source>Endocrinology</source> (<year>2005</year>) <volume>146</volume>:<fpage>4905</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="doi">10.1210/en.2005-0187</pub-id><?supplied-pmid 16109788?><pub-id pub-id-type="pmid">16109788</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clyne</surname><given-names>CD</given-names></name><name><surname>Kovacic</surname><given-names>A</given-names></name><name><surname>Speed</surname><given-names>CJ</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Pezzi</surname><given-names>V</given-names></name><name><surname>Simpson</surname><given-names>ER</given-names></name></person-group>. <article-title>Regulation of aromatase expression by the nuclear receptor LRH-1 in adipose tissue</article-title>. <source>Mol Cell Endocrinol</source> (<year>2004</year>) <volume>215</volume>:<fpage>39</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1016/j.mce.2003.11.001</pub-id><?supplied-pmid 15026173?><pub-id pub-id-type="pmid">15026173</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clyne</surname><given-names>CD</given-names></name><name><surname>Speed</surname><given-names>CJ</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Simpson</surname><given-names>ER</given-names></name></person-group>. <article-title>Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes</article-title>. <source>J Biol Chem</source> (<year>2002</year>) <volume>277</volume>:<fpage>20591</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M201117200</pub-id><?supplied-pmid 11927588?><pub-id pub-id-type="pmid">11927588</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annicotte</surname><given-names>JS</given-names></name><name><surname>Chavey</surname><given-names>C</given-names></name><name><surname>Servant</surname><given-names>N</given-names></name><name><surname>Teyssier</surname><given-names>J</given-names></name><name><surname>Bardin</surname><given-names>A</given-names></name><name><surname>Licznar</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene</article-title>. <source>Oncogene</source> (<year>2005</year>) <volume>24</volume>(<issue>55</issue>):<fpage>8167</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.1038/sj.onc.1208950</pub-id><?supplied-pmid 16091743?><pub-id pub-id-type="pmid">16091743</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianco</surname><given-names>S</given-names></name><name><surname>Brunelle</surname><given-names>M</given-names></name><name><surname>Jangal</surname><given-names>M</given-names></name><name><surname>Magnani</surname><given-names>L</given-names></name><name><surname>Gevry</surname><given-names>N</given-names></name></person-group>. <article-title>LRH-1 governs vital transcriptional programs in endocrine-sensitive and -resistant breast cancer cells</article-title>. <source>Cancer Res</source> (<year>2014</year>) <volume>74</volume>:<fpage>2015</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-2351</pub-id><?supplied-pmid 24520076?><pub-id pub-id-type="pmid">24520076</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chand</surname><given-names>AL</given-names></name><name><surname>Wijayakumara</surname><given-names>DD</given-names></name><name><surname>Knower</surname><given-names>KC</given-names></name><name><surname>Herridge</surname><given-names>KA</given-names></name><name><surname>Howard</surname><given-names>TL</given-names></name><name><surname>Lazarus</surname><given-names>KA</given-names></name><etal/></person-group>
<article-title>The orphan nuclear receptor LRH-1 and ERalpha activate GREB1 expression to induce breast cancer cell proliferation</article-title>. <source>PLoS One</source> (<year>2012</year>) <volume>7</volume>:<fpage>e31593</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0031593</pub-id><?supplied-pmid 22359603?><pub-id pub-id-type="pmid">22359603</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>CF</given-names></name><name><surname>Flach</surname><given-names>KD</given-names></name><name><surname>Alexi</surname><given-names>X</given-names></name><name><surname>Fox</surname><given-names>SP</given-names></name><name><surname>Ottaviani</surname><given-names>S</given-names></name><name><surname>Thiruchelvam</surname><given-names>PT</given-names></name><etal/></person-group>
<article-title>Co-regulated gene expression by oestrogen receptor alpha and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells</article-title>. <source>Nucleic Acids Res</source> (<year>2013</year>) <volume>41</volume>:<fpage>10228</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1093/nar/gkt827</pub-id><?supplied-pmid 24049078?><pub-id pub-id-type="pmid">24049078</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiruchelvam</surname><given-names>PT</given-names></name><name><surname>Lai</surname><given-names>CF</given-names></name><name><surname>Hua</surname><given-names>H</given-names></name><name><surname>Thomas</surname><given-names>RS</given-names></name><name><surname>Hurtado</surname><given-names>A</given-names></name><name><surname>Hudson</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells</article-title>. <source>Breast Cancer Res Treat</source> (<year>2011</year>) <volume>127</volume>:<fpage>385</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="doi">10.1007/s10549-010-0994-9</pub-id><?supplied-pmid 20607599?><pub-id pub-id-type="pmid">20607599</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miki</surname><given-names>Y</given-names></name><name><surname>Clyne</surname><given-names>CD</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Moriya</surname><given-names>T</given-names></name><name><surname>Shibuya</surname><given-names>R</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Immunolocalization of liver receptor homologue-1 (LRH-1) in human breast carcinoma: possible regulator of insitu steroidogenesis</article-title>. <source>Cancer Lett</source> (<year>2006</year>) <volume>244</volume>:<fpage>24</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1016/j.canlet.2005.11.038</pub-id><?supplied-pmid 16427184?><pub-id pub-id-type="pmid">16427184</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chand</surname><given-names>AL</given-names></name><name><surname>Herridge</surname><given-names>KA</given-names></name><name><surname>Thompson</surname><given-names>EW</given-names></name><name><surname>Clyne</surname><given-names>CD</given-names></name></person-group>. <article-title>The orphan nuclear receptor LRH-1 promotes breast cancer motility and invasion</article-title>. <source>Endocr Relat Cancer</source> (<year>2010</year>) <volume>17</volume>:<fpage>965</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.1677/ERC-10-0179</pub-id><?supplied-pmid 20817789?><pub-id pub-id-type="pmid">20817789</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazarus</surname><given-names>KA</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Knower</surname><given-names>KC</given-names></name><name><surname>To</surname><given-names>SQ</given-names></name><name><surname>Chand</surname><given-names>AL</given-names></name><name><surname>Clyne</surname><given-names>CD</given-names></name></person-group>. <article-title>Oestradiol reduces liver receptor homolog-1 mRNA transcript stability in breast cancer cell lines</article-title>. <source>Biochem Biophys Res Commun</source> (<year>2013</year>) <volume>438</volume>:<fpage>533</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbrc.2013.07.101</pub-id><?supplied-pmid 23911789?><pub-id pub-id-type="pmid">23911789</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chand</surname><given-names>AL</given-names></name><name><surname>Herridge</surname><given-names>KA</given-names></name><name><surname>Howard</surname><given-names>TL</given-names></name><name><surname>Simpson</surname><given-names>ER</given-names></name><name><surname>Clyne</surname><given-names>CD</given-names></name></person-group>. <article-title>Tissue-specific regulation of aromatase promoter II by the orphan nuclear receptor LRH-1 in breast adipose stromal fibroblasts</article-title>. <source>Steroids</source> (<year>2011</year>) <volume>76</volume>:<fpage>741</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1016/j.steroids.2011.02.024</pub-id><?supplied-pmid 21392518?><pub-id pub-id-type="pmid">21392518</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ariazi</surname><given-names>EA</given-names></name><name><surname>Kraus</surname><given-names>RJ</given-names></name><name><surname>Farrell</surname><given-names>ML</given-names></name><name><surname>Jordan</surname><given-names>VC</given-names></name><name><surname>Mertz</surname><given-names>JE</given-names></name></person-group>. <article-title>Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway</article-title>. <source>Mol Cancer Res</source> (<year>2007</year>) <volume>5</volume>:<fpage>71</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1158/1541-7786.MCR-06-0227</pub-id><?supplied-pmid 17259347?><pub-id pub-id-type="pmid">17259347</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerdin</surname><given-names>AK</given-names></name><name><surname>Surve</surname><given-names>VV</given-names></name><name><surname>Jonsson</surname><given-names>M</given-names></name><name><surname>Bjursell</surname><given-names>M</given-names></name><name><surname>Bjorkman</surname><given-names>M</given-names></name><name><surname>Edenro</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Phenotypic screening of hepatocyte nuclear factor (HNF) 4-gamma receptor knockout mice</article-title>. <source>Biochem Biophys Res Commun</source> (<year>2006</year>) <volume>349</volume>:<fpage>825</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbrc.2006.08.103</pub-id><?supplied-pmid 16945327?><pub-id pub-id-type="pmid">16945327</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deblois</surname><given-names>G</given-names></name><name><surname>Chahrour</surname><given-names>G</given-names></name><name><surname>Perry</surname><given-names>MC</given-names></name><name><surname>Sylvain-Drolet</surname><given-names>G</given-names></name><name><surname>Muller</surname><given-names>WJ</given-names></name><name><surname>Giguere</surname><given-names>V</given-names></name></person-group>. <article-title>Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis</article-title>. <source>Cancer Res</source> (<year>2010</year>) <volume>70</volume>:<fpage>10277</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2840</pub-id><?supplied-pmid 20961995?><pub-id pub-id-type="pmid">20961995</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deblois</surname><given-names>G</given-names></name><name><surname>Hall</surname><given-names>JA</given-names></name><name><surname>Perry</surname><given-names>MC</given-names></name><name><surname>Laganiere</surname><given-names>J</given-names></name><name><surname>Ghahremani</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Genome-wide identification of direct target genes implicates estrogen-related receptor alpha as a determinant of breast cancer heterogeneity</article-title>. <source>Cancer Res</source> (<year>2009</year>) <volume>69</volume>:<fpage>6149</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1251</pub-id><?supplied-pmid 19622763?><pub-id pub-id-type="pmid">19622763</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>SW</given-names></name><name><surname>Conneely</surname><given-names>OM</given-names></name><name><surname>DeMayo</surname><given-names>FJ</given-names></name><name><surname>O&#x02019;Malley</surname><given-names>BW</given-names></name></person-group>. <article-title>Identification of a new brain-specific transcription factor, NURR1</article-title>. <source>Mol Endocrinol</source> (<year>1992</year>) <volume>6</volume>:<fpage>2129</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1210/mend.6.12.1491694</pub-id><?supplied-pmid 1491694?><pub-id pub-id-type="pmid">1491694</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milbrandt</surname><given-names>J</given-names></name></person-group>. <article-title>Nerve growth factor induces a gene homologous to the glucocorticoid receptor gene</article-title>. <source>Neuron</source> (<year>1988</year>) <volume>1</volume>:<fpage>183</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/0896-6273(88)90138-9</pub-id><?supplied-pmid 3272167?><pub-id pub-id-type="pmid">3272167</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohkura</surname><given-names>N</given-names></name><name><surname>Hijikuro</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>A</given-names></name><name><surname>Miki</surname><given-names>K</given-names></name></person-group>. <article-title>Molecular cloning of a novel thyroid/steroid receptor superfamily gene from cultured rat neuronal cells</article-title>. <source>Biochem Biophys Res Commun</source> (<year>1994</year>) <volume>205</volume>:<fpage>1959</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1006/bbrc.1994.2900</pub-id><?supplied-pmid 7811288?><pub-id pub-id-type="pmid">7811288</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deutsch</surname><given-names>AJ</given-names></name><name><surname>Angerer</surname><given-names>H</given-names></name><name><surname>Fuchs</surname><given-names>TE</given-names></name><name><surname>Neumeister</surname><given-names>P</given-names></name></person-group>. <article-title>The nuclear orphan receptors NR4A as therapeutic target in cancer therapy</article-title>. <source>Anticancer Agents Med Chem</source> (<year>2012</year>) <volume>12</volume>:<fpage>1001</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.2174/187152012803529619</pub-id><?supplied-pmid 22583411?><pub-id pub-id-type="pmid">22583411</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llopis</surname><given-names>S</given-names></name><name><surname>Singleton</surname><given-names>B</given-names></name><name><surname>Duplessis</surname><given-names>T</given-names></name><name><surname>Carrier</surname><given-names>L</given-names></name><name><surname>Rowan</surname><given-names>B</given-names></name><name><surname>Williams</surname><given-names>C</given-names></name></person-group>. <article-title>Dichotomous roles for the orphan nuclear receptor NURR1 in breast cancer</article-title>. <source>BMC Cancer</source> (<year>2013</year>) <volume>13</volume>:<fpage>139</fpage>.<pub-id pub-id-type="doi">10.1186/1471-2407-13-139</pub-id><?supplied-pmid 23517088?><pub-id pub-id-type="pmid">23517088</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inamoto</surname><given-names>T</given-names></name><name><surname>Czerniak</surname><given-names>BA</given-names></name><name><surname>Dinney</surname><given-names>CP</given-names></name><name><surname>Kamat</surname><given-names>AM</given-names></name></person-group>. <article-title>Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer</article-title>. <source>Cancer</source> (<year>2010</year>) <volume>116</volume>:<fpage>340</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1002/cncr.24737</pub-id><?supplied-pmid 19908257?><pub-id pub-id-type="pmid">19908257</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohkubo</surname><given-names>T</given-names></name><name><surname>Ohkura</surname><given-names>N</given-names></name><name><surname>Maruyama</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>K</given-names></name><name><surname>Nagasaki</surname><given-names>K</given-names></name><name><surname>Hanzawa</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Early induction of the orphan nuclear receptor NOR-1 during cell death of the human breast cancer cell line MCF-7</article-title>. <source>Mol Cell Endocrinol</source> (<year>2000</year>) <volume>162</volume>:<fpage>151</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/S0303-7207(00)00222-7</pub-id><?supplied-pmid 10854708?><pub-id pub-id-type="pmid">10854708</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forman</surname><given-names>BM</given-names></name><name><surname>Umesono</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>RM</given-names></name></person-group>. <article-title>Unique response pathways are established by allosteric interactions among nuclear hormone receptors</article-title>. <source>Cell</source> (<year>1995</year>) <volume>81</volume>:<fpage>541</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1016/0092-8674(95)90075-6</pub-id><?supplied-pmid 7758108?><pub-id pub-id-type="pmid">7758108</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perlmann</surname><given-names>T</given-names></name><name><surname>Jansson</surname><given-names>L</given-names></name></person-group>. <article-title>A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and NURR1</article-title>. <source>Genes Dev</source> (<year>1995</year>) <volume>9</volume>:<fpage>769</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1101/gad.9.7.769</pub-id><?supplied-pmid 7705655?><pub-id pub-id-type="pmid">7705655</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruyama</surname><given-names>K</given-names></name><name><surname>Tsukada</surname><given-names>T</given-names></name><name><surname>Bandoh</surname><given-names>S</given-names></name><name><surname>Sasaki</surname><given-names>K</given-names></name><name><surname>Ohkura</surname><given-names>N</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name></person-group>. <article-title>Retinoic acids differentially regulate NOR-1 and its closely related orphan nuclear receptor genes in breast cancer cell line MCF-7</article-title>. <source>Biochem Biophys Res Commun</source> (<year>1997</year>) <volume>231</volume>:<fpage>417</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1006/bbrc.1997.6122</pub-id><?supplied-pmid 9070291?><pub-id pub-id-type="pmid">9070291</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacroix</surname><given-names>A</given-names></name><name><surname>Lippman</surname><given-names>ME</given-names></name></person-group>. <article-title>Binding of retinoids to human breast cancer cell lines and their effects on cell growth</article-title>. <source>J Clin Invest</source> (<year>1980</year>) <volume>65</volume>:<fpage>586</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1172/JCI109703</pub-id><?supplied-pmid 7188772?><pub-id pub-id-type="pmid">7188772</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>M</given-names></name><name><surname>Fenig</surname><given-names>E</given-names></name><name><surname>Rosenauer</surname><given-names>A</given-names></name><name><surname>Menendez-Botet</surname><given-names>C</given-names></name><name><surname>Achkar</surname><given-names>C</given-names></name><name><surname>Bentel</surname><given-names>JM</given-names></name><etal/></person-group>
<article-title>9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein</article-title>. <source>Cancer Res</source> (<year>1994</year>) <volume>54</volume>:<fpage>6549</fpage>&#x02013;<lpage>56</lpage>.<?supplied-pmid 7987855?><pub-id pub-id-type="pmid">7987855</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Burg</surname><given-names>B</given-names></name><name><surname>van der Leede</surname><given-names>BM</given-names></name><name><surname>Kwakkenbos-Isbrucker</surname><given-names>L</given-names></name><name><surname>Salverda</surname><given-names>S</given-names></name><name><surname>de Laat</surname><given-names>SW</given-names></name><name><surname>van der Saag</surname><given-names>PT</given-names></name></person-group>. <article-title>Retinoic acid resistance of estradiol-independent breast cancer cells coincides with diminished retinoic acid receptor function</article-title>. <source>Mol Cell Endocrinol</source> (<year>1993</year>) <volume>91</volume>:<fpage>149</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1016/0303-7207(93)90267-N</pub-id><?supplied-pmid 8386111?><pub-id pub-id-type="pmid">8386111</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Dily</surname><given-names>F</given-names></name><name><surname>Metivier</surname><given-names>R</given-names></name><name><surname>Gueguen</surname><given-names>MM</given-names></name><name><surname>Le Peron</surname><given-names>C</given-names></name><name><surname>Flouriot</surname><given-names>G</given-names></name><name><surname>Tas</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>COUP-TFI modulates estrogen signaling and influences proliferation, survival and migration of breast cancer cells</article-title>. <source>Breast Cancer Res Treat</source> (<year>2008</year>) <volume>110</volume>:<fpage>69</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1007/s10549-007-9693-6</pub-id><?supplied-pmid 17674191?><pub-id pub-id-type="pmid">17674191</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagasaki</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Miki</surname><given-names>Y</given-names></name><name><surname>Akahira</surname><given-names>J</given-names></name><name><surname>Shibata</surname><given-names>H</given-names></name><name><surname>Ishida</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Chicken ovalbumin upstream promoter transcription factor II in human breast carcinoma: possible regulator of lymphangiogenesis via vascular endothelial growth factor-C expression</article-title>. <source>Cancer Sci</source> (<year>2009</year>) <volume>100</volume>:<fpage>639</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1111/j.1349-7006.2008.01078.x</pub-id><pub-id pub-id-type="pmid">19154418</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metivier</surname><given-names>R</given-names></name><name><surname>Gay</surname><given-names>FA</given-names></name><name><surname>Hubner</surname><given-names>MR</given-names></name><name><surname>Flouriot</surname><given-names>G</given-names></name><name><surname>Salbert</surname><given-names>G</given-names></name><name><surname>Gannon</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Formation of an hER alpha-COUP-TFI complex enhances hER alpha AF-1 through Ser118 phosphorylation by MAPK</article-title>. <source>EMBO J</source> (<year>2002</year>) <volume>21</volume>:<fpage>3443</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1093/emboj/cdf344</pub-id><?supplied-pmid 12093745?><pub-id pub-id-type="pmid">12093745</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boudot</surname><given-names>A</given-names></name><name><surname>Kerdivel</surname><given-names>G</given-names></name><name><surname>Lecomte</surname><given-names>S</given-names></name><name><surname>Flouriot</surname><given-names>G</given-names></name><name><surname>Desille</surname><given-names>M</given-names></name><name><surname>Godey</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>COUP-TFI modifies CXCL12 and CXCR4 expression by activating EGF signaling and stimulates breast cancer cell migration</article-title>. <source>BMC Cancer</source> (<year>2014</year>) <volume>14</volume>:<fpage>407</fpage>.<pub-id pub-id-type="doi">10.1186/1471-2407-14-407</pub-id><?supplied-pmid 24906407?><pub-id pub-id-type="pmid">24906407</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>L</given-names></name><name><surname>Thomsen</surname><given-names>JS</given-names></name><name><surname>Damdimopoulos</surname><given-names>AE</given-names></name><name><surname>Spyrou</surname><given-names>G</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name><name><surname>Treuter</surname><given-names>E</given-names></name></person-group>. <article-title>The orphan nuclear receptor SHP inhibits agonist-dependent transcriptional activity of estrogen receptors ERalpha and ERbeta</article-title>. <source>J Biol Chem</source> (<year>1999</year>) <volume>274</volume>:<fpage>345</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.274.1.345</pub-id><?supplied-pmid 9867849?><pub-id pub-id-type="pmid">9867849</pub-id></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovacic</surname><given-names>A</given-names></name><name><surname>Speed</surname><given-names>CJ</given-names></name><name><surname>Simpson</surname><given-names>ER</given-names></name><name><surname>Clyne</surname><given-names>CD</given-names></name></person-group>. <article-title>Inhibition of aromatase transcription via promoter II by short heterodimer partner in human preadipocytes</article-title>. <source>Mol Endocrinol</source> (<year>2004</year>) <volume>18</volume>:<fpage>252</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1210/me.2003-0211</pub-id><?supplied-pmid 14593077?><pub-id pub-id-type="pmid">14593077</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sengupta</surname><given-names>D</given-names></name><name><surname>Bhargava</surname><given-names>DK</given-names></name><name><surname>Dixit</surname><given-names>A</given-names></name><name><surname>Sahoo</surname><given-names>BS</given-names></name><name><surname>Biswas</surname><given-names>S</given-names></name><name><surname>Biswas</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>ERRbeta signalling through FST and BCAS2 inhibits cellular proliferation in breast cancer cells</article-title>. <source>Br J Cancer</source> (<year>2014</year>) <volume>110</volume>:<fpage>2144</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="doi">10.1038/bjc.2014.53</pub-id><?supplied-pmid 24667650?><pub-id pub-id-type="pmid">24667650</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giguere</surname><given-names>V</given-names></name></person-group>
<article-title>Orphan nuclear receptors: from gene to function</article-title>. <source>Endocr Rev</source> (<year>1999</year>) <volume>20</volume>:<fpage>689</fpage>&#x02013;<lpage>725</lpage>.<pub-id pub-id-type="doi">10.1210/edrv.20.5.0378</pub-id><pub-id pub-id-type="pmid">10529899</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Kiriyama</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>KY</given-names></name><name><surname>Giguere</surname><given-names>V</given-names></name></person-group>. <article-title>Transcriptional regulation of the estrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan nuclear receptors</article-title>. <source>Cancer Res</source> (<year>2001</year>) <volume>61</volume>(<issue>18</issue>):<fpage>6755</fpage>&#x02013;<lpage>61</lpage>.<?supplied-pmid 11559547?><pub-id pub-id-type="pmid">11559547</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanida</surname><given-names>T</given-names></name><name><surname>Matsuda</surname><given-names>KI</given-names></name><name><surname>Yamada</surname><given-names>S</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Kawata</surname><given-names>M</given-names></name></person-group>. <article-title>Estrogen-related receptor beta reduces the subnuclear mobility of estrogen receptor alpha and suppresses estrogen-dependent cellular function</article-title>. <source>J Biol Chem</source> (<year>2015</year>) <volume>290</volume>:<fpage>12332</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M114.619098</pub-id><?supplied-pmid 25805499?><pub-id pub-id-type="pmid">25805499</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Cooney</surname><given-names>AJ</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Law</surname><given-names>SW</given-names></name><name><surname>O&#x02019;Malley</surname><given-names>BW</given-names></name></person-group>. <article-title>Cloning of a novel orphan receptor (GCNF) expressed during germ cell development</article-title>. <source>Mol Endocrinol</source> (<year>1994</year>) <volume>8</volume>:<fpage>1434</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1210/me.8.10.1434</pub-id><?supplied-pmid 7854358?><pub-id pub-id-type="pmid">7854358</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Cooney</surname><given-names>AJ</given-names></name></person-group>. <article-title>Revisiting the role of GCNF in embryonic development</article-title>. <source>Semin Cell Dev Biol</source> (<year>2013</year>) <volume>24</volume>:<fpage>679</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="doi">10.1016/j.semcdb.2013.08.003</pub-id><?supplied-pmid 24029702?><pub-id pub-id-type="pmid">24029702</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>ZJ</given-names></name><name><surname>Gu</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Jackson</surname><given-names>KJ</given-names></name><name><surname>DeMayo</surname><given-names>FJ</given-names></name><name><surname>O&#x02019;Malley</surname><given-names>BW</given-names></name><etal/></person-group>
<article-title>GCNF-dependent repression of BMP-15 and GDF-9 mediates gamete regulation of female fertility</article-title>. <source>EMBO J</source> (<year>2003</year>) <volume>22</volume>:<fpage>4070</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1093/emboj/cdg405</pub-id><?supplied-pmid 12912906?><pub-id pub-id-type="pmid">12912906</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willis</surname><given-names>S</given-names></name><name><surname>De</surname><given-names>P</given-names></name><name><surname>Dey</surname><given-names>N</given-names></name><name><surname>Long</surname><given-names>B</given-names></name><name><surname>Young</surname><given-names>B</given-names></name><name><surname>Sparano</surname><given-names>JA</given-names></name><etal/></person-group>
<article-title>Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs</article-title>. <source>Meta Gene</source> (<year>2015</year>) <volume>4</volume>:<fpage>129</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1016/j.mgene.2015.04.002</pub-id><?supplied-pmid 26005638?><pub-id pub-id-type="pmid">26005638</pub-id></mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gyorffy</surname><given-names>B</given-names></name><name><surname>Lanczky</surname><given-names>A</given-names></name><name><surname>Eklund</surname><given-names>AC</given-names></name><name><surname>Denkert</surname><given-names>C</given-names></name><name><surname>Budczies</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><etal/></person-group>
<article-title>An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients</article-title>. <source>Breast Cancer Res Treat</source> (<year>2010</year>) <volume>123</volume>:<fpage>725</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1007/s10549-009-0674-9</pub-id><?supplied-pmid 20020197?><pub-id pub-id-type="pmid">20020197</pub-id></mixed-citation></ref></ref-list></back></article>